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1 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 1.1 Neuropeptide Y 
1.1 Neuropeptide Y 
Neuropeptide Y (NPY), a highly conserved 36-amino acid peptide neurotransmitter, was first 
isolated by Tatemoto et al. from porcine brain in 1982 (Tatemoto et al., 1982). It is one of the 
most abundant neuropeptides in the mammalian brain and structurally and functionally 
related to pancreatic peptide (PYY) and pancreatic polypeptide (PP) (Figure 1.1) (Michel et 
al., 1998). For all these peptides, C-terminal amidation is essential for biological activity 
(Wahlestedt et al., 1986). Between mammals, 22 positions are identical in all NPY 
sequences known (for reviews cf. (Merten and Beck-Sickinger, 2006; Mörl and Beck-
Sickinger, 2015)). 
 
 
Figure 1.1. Amino acid sequences of hNPY, pNPY hPYY and hPP. Constant positions in all species 
for the peptides are underlined. The seven constant residues within the NPY-family are indicated 
(boxed) (Larhammar, 1996). 
In the periphery NPY is abundant in sympathetic neurons, where it is co-stored and co-
released with noradrenaline, and it was also found in the parasympathetic nervous system 
(Sundler et al., 1993; von Hörsten et al., 2004). In the central nervous system (CNS) NPY 
was found in numerous brain regions including basal ganglia, hypothalamus, amygdala, 
hippocampus, locus coeruleus, nucleus accumbens, and the cerebral cortex (Chronwall, 
1985; Fetissov et al., 2004; Heilig and Widerlov, 1995). The NPY receptors are involved in 
the regulation of numerous physiological processes such as blood pressure, food intake, 
pain sensitivity, anxiety/anxiolysis, depression and hormone release (Brothers and 
Wahlestedt, 2010; Yulyaningsih et al., 2011). Recent reviews give an overview of the role of 
NPY (Gotzsche and Woldbye, 2016; Reichmann and Holzer, 2016; Tasan et al., 2016). 
 
1.2 NPY receptors and their ligands 
The physiological functions of NPY family of peptides are mediated by Y receptors which 
belong to the rhodopsin-like Gi coupled G protein-coupled receptor (GPCR) family. Four 
functional NPY receptor subtypes, designated Y1R, Y2R, Y4R, and Y5R, have been identified 
in humans (Blomqvist and Herzog, 1997; Bromee et al., 2006; Salaneck et al., 2008). Among 
the NPY receptors, the Y4R is unique, as it prefers PP over NPY and PYY as the 
endogenous ligand. The y6R is functional expressed in rabbit and mouse, while no y6 gene 
was detected in rat (Burkhoff et al., 1998). In humans and other primates, the receptor is 
non-functional because of a frameshift mutation (single base deletion) in the third intracellular 
YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2  hNPY (1) 
YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY-NH2  pNPY (2) 
YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2  hPYY 
APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2  hPP  (3) 
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loop leading to a truncated receptor protein after the 6th transmembrane region (Rose et al., 
1997). The main signal transduction pathway of NPY receptors results in an inhibition of 
adenylyl cyclase mediated cAMP formation (Holliday et al., 2004; Michel et al., 1998). 
Additionally, elevation of the intracellular calcium concentration after NPY receptor 
stimulation has been shown in cells natively expressing (Michel et al., 1998; Müller et al., 
1997) as well as in cells heterologously expressing NPY receptors (Bard et al., 1995; Gerald 
et al., 1995; Grouzmann et al., 2001; Selbie et al., 1995). Nevertheless, the Ca2+ response 
upon NPY receptor activation depends on the cell type (Wahlestedt et al., 1986). An 
overview of the most important characteristics of NPY receptors is given in Table 1.1 (for 
NPY receptor ligands see sections 1.2.1 and 1.2.2). 
 
Table 1.1. Characteristics of the mammalian NPY receptor subtypes (adapted from (Merten 
and Beck-Sickinger, 2006)). 
Y1R  
Receptor properties 384 amino acids (AA), highly conserved, 90–96% overall identity across 
mammals  
Expression pattern Cerebral cortex, vascular smooth muscle cells, colon, human adipocytes 
Physiological functions Analgesia, anxiolysis, circadian rhythm regulation, endocrine regulation, 
increase in feeding, sedative, vasoconstriction 
Ligand binding profile NPY ≈ PYY ≈ [Leu31,Pro34]NPY > NPY2-36 ≈ NPY3-36 ≥ PP ≈ NPY13-36 
Y2R  
Receptor properties 381 AA, highly conserved across species (sequence homology > 90%;   
~ 80% identity mammalian compared to chicken Y2R) 
Expression pattern Nerve fibers, hippocampus, intestine, blood vessels 
Physiological functions Angiogenesis, anxiogenesis, enhanced memory, decreased 
neurotransmitter secretion, decrease feeding, anticonvulsant 
Ligand binding profile PYY > PYY3-36 ≈ NPY3-36 ≈ NPY2-36 ≈ NPY13-36 >>[Leu31,Pro34]NPY 
Y4R  
Receptor properties 375 AA, 74–86% sequence homology across species  
Expression pattern Hypothalamus, skeletal muscle, thyroid gland, stomach, small intestine, 
colon 
Physiological functions Pancreatic secretion, gall bladder contraction, LH secretion, decrease 
feeding 
Ligand binding profile PP ≥ GW1229 > PYY ≥ NPY > NPY2-36 
 
4 1.2 NPY receptors and their ligands 
Y5R  
Receptor properties 445 AA, 82–95% overall identity between different mammals 
Expression pattern Hypothalamus, cerebral cortex, intestine, ovary, spleen, pancreas, 
skeletal muscle 
Physiological functions Circadian rhythm regulation, increase in feeding, anticonvulsant, 
reproduction 
Ligand binding profile NPY ≈ PYY ≈ NPY2-36 ≈ [Leu31,Pro34]NPY > hPP >[D-Trp32]NPY 
> NPY13-36 > rPP 
 
 
1.2.1 The NPY Y1, Y2 and Y5 receptors and their ligands 
The Y1 receptor was the first “PP-fold peptide” binding receptor to be cloned. Across all 
species, the Y1 receptor displays more than 95% amino acid sequence identity in the 
transmembrane regions (Larhammar et al., 2001). High affinity for NPY and PYY and a low 
affinity for PP are characteristic of the Y1 receptor (Cabrele and Beck-Sickinger, 2000). In the 
last years, a library of selective and highly potent non-peptidic Y1R antagonists with affinities 
in the nanomolar and subnanomolar range have been developed, including the 
argininamides BIBP3226 and BIBO3304 (Rudolf et al., 1994; Wieland et al., 1998) (for a 
recent review on Y1 antagonists cf. (Moreno-Herrera et al., 2014). Bioisosteric replacement of 
the guanidine group in BIBP3226 by an acyl- or carbamoylguanidine moiety afforded ligands 
with increased Y1R affinity, including the radiolabeled Y1R antagonists [3H]UR-MK114 (Keller 
et al., 2008) and [3H]UR-MK136 (Keller et al., 2011). Both compounds turned out to be high-
affinity selective radioligands for the Y1R. Recently, focussing on Nω-carbamoylated 
argininamides, [3H]UR-MK299 (Keller et al., 2015b) proved to be by far superior to the 
homolog [3H]UR-MK136 regarding affinity and target residence time. Structural modifications 
of the argininamide-type Y1R antagonist BIBO3304 were tolerated as well and led to highly 
selective antagonists with affinities in the single-digit nanomolar range, suggesting the 
preparation of radiolabeled analogs (Keller et al., 2015a). A selection of non‐peptidic Y1R 
antagonists is shown in Figure 1.2. 
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Figure 1.2. Examples of non-peptidic selective Y1R ligands. a(Rudolf et al., 1994), b(Wieland et al., 
1998), c(Keller et al., 2008), d(Keller et al., 2011), e(Keller et al., 2015b), f(Kanatani et al., 1999), 
g(Kanatani et al., 2001)  
 
Originally, the Y2 receptor was postulated based on pharmacological studies with amino 
terminally truncated fragments of NPY and PYY, such as NPY3-36 and NPY13-36, using 
vascular preparations (Wahlestedt et al., 1986). In contrast to the Y1 receptor, the truncated 
peptides were full agonists with similar potency as the native peptides at the postulated Y2 
receptor. A detailed structural model of NPY bound to the Y2R suggested that larger peptide 
ligands also share the proposed common ligand binding cradle of rhodopsin-like GPCRs 
(Venkatakrishnan et al., 2013), even if they are not expected to bind deep in the 
transmembrane bundle. It was concluded from NMR studies that changes in the C-terminal 
amino acids can easily disturb receptor binding or switch receptor selectivity (Kaiser et al., 
2015; Pedragosa Badia et al., 2013). Human cells endogenously expressing the Y2R, for 
example SMS-KAN (Shigeri and Fujimoto, 1994), LN319 (Beck-Sickinger et al., 1992), CHP-
234 (Lynch et al., 1994) and MHH‐NB‐11 cells (Hofliger et al., 2003), have a broad 
application for investigations on Y2R mediated cellular reponses. Very recently, a molecular 
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basis was established to elucidate the actions of chicken Y2, Y5 and Y7 receptors and their 
ligands in birds which may be helpful to uncover the conserved roles of these ligand-receptor 
pairs in vertebrates (He et al., 2016).  
In 1999 the argininamide BIIE0246 was described as the first potent and selective Y2R 
antagonist (Doods et al., 1999; Dumont et al., 2000). In the last decade, the Y2R was put into 
focus as a potential therapeutic target, not least by brain penetrant, orally available Y2R 
antagonists such as JNJ-31020028 (Shoblock et al., 2010), JNJ-5207787 (Bonaventure et 
al., 2004), SF-11 (Brothers et al., 2010) and analogs (cf. review (Mittapalli and Roberts, 
2014). In our workgroup, a library of derivatives of the argininamide BIIE0246, including 
radiolabeled and fluorescence-labeled ligands, was synthesized and characterized at CHO 
cells stably expressing the hY2R (Pluym et al., 2011). Most compounds showed Y2R 
antagonistic activities and binding affinities similar to those of BIIE0246, confirming that the 
guanidine–acylguanidine replacement is an effective non-conventional bioisosteric approach 
(Pluym et al., 2011). Acylation with succinimidyl [3H]propionate resulted in selective non-
peptide radioligands [3H]UR-PLN196 and [3H]UR-PLN208 as pharmacological tools 
(Baumeister, 2014; Pluym et al., 2013). Very recently, docking studies showed that binding 
sites of BIIE0246 and SF-11 derivatives overlap with that of the endogenous agonist NPY. It 
is suggested that these antagonists share the same deep, hydrophobic binding pocket (L4.60, 
L5.46, L6.51) and interact with TM2 and TM7 (Y2.64, F7.35). The interaction with D6.59 is only 
observed in case of BIIE0246 (Burkert et al., 2016). A selection of Y2R ligands is depicted in 
Figure 1.3. 
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Figure 1.3. Structures of selected Y2R antagonists. a(Doods et al., 1999), b(Pluym et al., 2013), 
c(Baumeister, 2014), d(Shoblock et al., 2010), e(Bonaventure et al., 2004), f(Brothers and Wahlestedt, 
2010) 
 
In 1992, the Y5 receptor was first proposed as a variant of the Y1R based on the observation 
that NPY and NPY2-36 produced a strong increase in food intake after 
intracerebroventricular administration in rats (Stanley et al., 1992). The first Y5 selective 
agonist [Ala31,Aib32]NPY (Aib = aminoisobutyric acid) was active in a cAMP assay and was 
also able to induce feeding in rats (Cabrele et al., 2000). In 1997, the first selective Y5R 
antagonist was reported (Criscione L, 1997). CGP 71683A showed more than 1000-fold 
affinity to the Y5R compared to the Y1, Y2 and Y4 subtypes (Criscione et al., 1998). Due to off-
target effects CGP 71683A is not an ideal tool to investigate the role of the Y5 receptor in the 
regulation of food consumption in vivo (Della Zuana et al., 2001). However, the discovery of 
this compound stimulated the search for Y5R antagonists as potential drugs for the treatment 
of obesity (Moreno-Herrera et al., 2014). Meanwhile, this approach is no longer considered 
promising. Very recently, a correlation between high serum NPY and metastases was 
reported. Increased Y5R expression in angioinvasive neuroblastoma implicates that the 
8 1.2 NPY receptors and their ligands 
NPY/Y5R axis as a metastatic pathway and patients with disseminated disease could be 
identified as a candidate for anti-NPY therapy. Due to high systemic NPY levels with disease 
relapse, the clinical utility as a minimally invasive biomarker for monitoring neuroblastoma 
progression could be important in future therapy (Galli et al., 2016). A selection of Y5R 
antagonists with Ki values in the low nanomolar range is given in Figure 1.4. 
 
 
Figure 1.4. Selection of Y5R antagonists. a(Criscione et al., 1998), b(Kanatani et al., 2000), c(Erondu et 
al., 2006), d(Walker et al., 2009) 
 
 
1.2.2 The NPY Y4 receptor and its ligands 
The Y4R shares only low sequence identity with the other NPY receptor subtypes and is an 
exception as it prefers PP as endogenous ligand (Lundell et al., 1995). First insights into the 
complex binding pocket of the hY4R system, derived from a combination of modelling and 
mutagenesis, were recently described. According to this study the top of trans-membrane 
helix 2 (TM2) and the top of transmembrane helices 6 and 7 (TM6-TM7) form the core of the 
peptide binding pocket (Pedragosa-Badia et al., 2014). 
The Y4R shares the highest sequence identity (42%) with the Y1R. A similarity between both 
receptors is also reflected by the Y4R affinity of several ligands, which were initially designed 
as Y1R antagonists, for example, the ‘dimeric ligands’ GW1229 (4) (Parker et al., 1998), a Y1 
antagonist/Y4 agonist, and the non-peptidic Y1 antagonist/Y4 antagonist UR-MK188 (Keller et 
al., 2013). This suggests that Y4R antagonists may be identified among or developed from 
known Y1R ligands. Another example of a highly potent Y4 receptor agonist is D/L-2,7-
diaminooctanedioyl-bis(YRLRY-NH2) (BVD-74D), a diastereomeric mixture of D/L-(2,7)-BVD-
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74D (Balasubramaniam et al., 2006). Derived from the C-terminal pentapeptide of hPP, the 
respective pure diastereomers and a series of homo- and heterodimeric analogs were 
synthesized in our working group. In binding and functional cellular assays, (2R,7R)-BVD-
74D was superior to (2S,7S)-BVD-74D, and two analogs gave access to the corresponding 
tritiated high affinity Y4R radioligands [³H]UR-KK193 (5) and [³H]UR-KK200 (Kuhn et al., 
2016). Recently, a fluorescently labeled analog of BVD-74D, (sulfo-Cy5) labeled (R,R)-
analog (mono-sCy5-(2R,7R)-sub(YRLRY-NH2)2) was reported as a novel Y4R agonist with 
nanomolar affinity (Liu et al., 2016). 
With regard to the potential therapeutic use of Y4R agonists, peptides with increased stability 
in plasma were developed. Lipidation and PEGylation of PP not only prolonged plasma half‐
life but also inhibited arrestin recruitment and receptor internalization (Mäde et al., 2014). 
Behavioural experiments with mice upon peripheral injection of a novel PEGylated derivative 
of PP, the selective Y4R agonist [K30(PEG2)]hPP2‐36, suggest that these derivatives 
penetrate across the blood-brain barrier (Verma et al., 2016). 
Truncated hPP analogs such as [Nle30]hPP25−36 and [Leu34]pNPY25−36 were found to be 
Y4R selective partial agonists (Berlicki et al., 2013). [Ala27]hPP and [Leu27]hPP were used to 
localize specific interactions between hPP and the hY4R (Pedragosa-Badia et al., 2014). Full-
length PP/NPY chimeras were designed and characterized by Cabrele et al. (Cabrele et al., 
2001). Aiming at labeled hPP derivatives using amino-reactive reagents the amino acid in 
position 4 was replaced by lysine ([Lys4]hPP, 7). This gave access to the fluorescent 
peptides S0586- and cy5-[Lys4]hPP, which turned out to be valuable pharmacological tools 
for the investigation of Y4R ligands, e. g. by flow cytometry or confocal microscopy (Ziemek, 
2006; Ziemek et al., 2007). A selection of Y4R ligands is given in Figure 1.5. 
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Figure 1.5. Structures of selected peptidic agonists and the non-peptidic antagonist UR-MK188. 
a(Parker et al., 1998), b(Balasubramaniam et al., 2006), c(Kuhn et al., 2016), d(Keller et al., 2013) 
 
1.3 Sodium sensitivity of the NPY receptors 
GPCR agonist binding and/or G-protein activation may depend on allosteric inhibition by 
sodium ions. In high-resolution structures of the human A2A adenosine receptor (Liu et al., 
2012), the ß1 adrenergic receptor (Miller-Gallacher et al., 2014) and μ-opioid receptor (Huang 
et al., 2015) in the inactive state, Na+ allosteric sites were identified. In case of NPY 
receptors, sensitivity of PP binding to sodium ions and to modulators of sodium transport was 
reported (Parker et al., 2002; Parker et al., 2000; Parker S.L., 2001; Parker et al., 2001; 
Parker and Parker, 2000a; b; Parker et al., 1999). 
In functional studies, the effects of monovalent cations and anions were investigated using 
the steady-state GTPase assay at the hY2R and hY4R. At the hY2R no effect of sodium was 
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observed, whereas the agonistic potency of GW1229 at the hY4R was decreased by a factor 
of 8.4 in the presence of sodium (Pop et al., 2011). Very recent results from radioligand 
binding experiments support previous findings that the affinity of peptidic Y4R agonists is 
considerably lower in the presence of sodium ions (Kuhn et al., 2016).  
 
1.4 Tritium- and fluorescence-labeled NPY receptor ligands 
1.4.1 Tritiated radioligands 
In view of the long half-life and the convenient accessibility tritiated ligands are preferred in 
our laboratory. Labeling of amine precursors by conjugation with commercially available 
succinimidyl [3H]propionate has been successfully performed in case of both, peptide 
agonists and nonpeptide antagonists. For instance, [³H]propionyl-pNPY, acylated at Lys4, 
has been used as a universal ligand of Y1, Y2 and Y5 receptors in saturation and competition 
binding studies(Chang et al., 1988; Keller et al., 2015b; Kuhn et al., 2016; Widdowson and 
Halaris, 1990). Recently, in search for subtype-selective radioligands, different approaches 
afforded the tritiated ligands [³H]UR-MK299 (Keller et al., 2015b), an antagonist at the Y1R, 
the Y2R antagonist [³H]UR-PLN196 (Pluym et al., 2013) and the Y4R selective agonist 
[³H]UR-KK193 (Kuhn et al., 2016).  
 
 
1.4.2 Fluorescent ligands for cellular investigations 
Fluorescent ligands enable cellular investigations, which are, except for saturation and 
competition binding, complementary to studies with radioligands. Techniques such as flow 
cytometry enable the determination of binding affinities of compounds and the binding 
kinetics of the labeled ligand at the receptor. Furthermore, receptor localization and 
internalization can be visualized by confocal laser scanning microscopy, which is an 
indispensable tool for GPCR imaging. For such studies the selection of appropriate 
fluorophores is essential to optimize the signal-to-noise ratio. In the NPY receptor field, 
investigations with specifically bound fluorescent peptides, e.g. BODIPY®-NPY peptide 
analogs led to new insights in internalization and cellular trafficking processes (Dumont et al., 
2005). The fluorescent peptide Cy5-pNPY (Schneider et al., 2006; Ziemek et al., 2006) was 
applied as a universal ligand for Y1, Y2 and Y5 receptors, for example, for the determination 
of the NPY receptor subtype selectivity of novel compounds (Kaske, 2012; Pluym, 2011). 
Regarding the preferred synthesis of selective fluorescent ligands, the Py-1 labeled Y1R 
antagonist UR-MK22 (Memminger et al., 2012; Schneider et al., 2007) and several Y2R 
antagonists with various fluorophores (Pluym, 2011) were synthesized in our working group. 
For example, the expression of the Y1R in MCF-7 cells was confirmed by the binding of UR-
MK22. Selective Y4R agonists such as Cy5-[Lys4]hPP (Ziemek et al., 2007) and a sCy5 
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labeled fluorescent analog of BVD-74D (Liu et al., 2016) have been used for Y4R imaging 
and binding studies. 
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2 Scope and objectives 
  
20  Scope 
Binding and functional assays are indispensable for the characterization of GPCR ligands. 
One part of this thesis is aiming at establishing functional assays for the hY2R and hY4R. The 
[35S]GTPγS binding assay and the luciferase gene reporter assay complement each other, 
since they provide different readouts. In the [35S]GTPγS assay, receptor-mediated activation 
is measured directly at the G-protein level as a proximal effect of ligand binding without 
signal amplification. Moving down the signaling pathway, the activation (or inhibition) of 
transcription is the approach of the luciferase gene reporter assay, providing a convenient 
optical readout. For validation of the assays, a library of known Y2R and Y4R ligands 
including agonists and antagonists will be investigated at optimized assay conditions and 
compared with data reported in literature.  
Several fluorescent or radiolabeled peptides have been used as pharmacological tools for 
the investigation of NPY receptor subtypes. However, there is a need especially for labeled 
Y4R selective ligands. Previously, the fluorescent peptides Cy5- and S0586-[Lys4]hPP 
(Ziemek et al., 2007) were synthesized and characterized in our working group and 
successfully used in flow cytometric saturation and competition binding assays. However, 
these peptides contain two methionine residues which are prone to oxidation during storage, 
resulting in mixtures of products (sulfoxides, sulfones). The consequences in terms of affinity 
and selectivity were unclear. Therefore, the aim is to obtain stable radiolabeled and 
fluorescent Y4R ligands by derivatization of a [Lys4]hPP analog, [Lys4,Nle17,30]hPP, containing 
norleucine instead of methionine. These molecular tools will be used for investigations at the 
Y4R, e.g. in saturation, kinetic and competition binding assays. The applicability of the 
fluorescent ligand to flow cytometry and confocal microscopy will be explored, e. g. to 
investigate receptor internalization. Special attention will be paid to the investigation of the 
influence of the osmolarity and the composition of buffers on ligand binding and 
internalization.  
 
Reference: 
Ziemek, R.; Schneider, E.; Kraus, A.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; 
Buschauer, A. (2007). Determination of Affinity and Activity of Ligands at the Human 
Neuropeptide Y Y4 Receptor by Flow Cytometry and Aequorin Luminescence. J. 
Recept. Signal Transduct. Res. 27(4): 217-233. 
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3 Development of a [35S]GTPγS binding 
assay for hY2 and hY4 receptors in Sf9 
membranes 
  
22 3.1 Introduction 
3.1 Introduction 
Since binding assays provide only information about affinities, there is a need for functional 
assays to categorize ligands into agonists, inverse agonists and antagonists (Milligan, 2003). 
As all NPY receptor subtypes are coupling to Gi/o, stimulation of the receptors leads to an 
inhibition of adenylyl cyclase resulting in a decreased formation of cAMP. This effect is 
commonly used in assays based on the inhibition of forskolin-induced cAMP formation 
(Beck-Sickinger et al., 1992; Goumain et al., 2001). Furthermore, potencies of Y2 and Y4 
receptor ligands can be determined by measuring tritium-labeled phosphoinositol 
accumulation, when COS-7 cells are co-transfected with YRs and chimeric G proteins 
(Merten et al., 2007). The mobilization of intracellular calcium in HEK293 cells can be 
measured fluorimetrically when the YR subtype of interest (Dautzenberg et al., 2005) is co-
expressed with chimeric G-proteins such as Gqi5 to redirect the signal to the phospholipase 
C pathway. By analogy, aequorin-based bioluminescence can be used for the determination 
of ligand activity at the Y2R and the Y4R (Ziemek et al., 2006; Ziemek et al., 2007). In 
addition, the steady-state GTPase assay provides a proximal readout for functional studies 
on membrane preparations of Sf9 insect cells (Pop et al., 2011). Receptor-mediated 
activation is measured directly at the G-protein level as a proximal effect of agonist binding, 
which also holds for the [35S]GTPγS assay (Dautzenberg et al., 2005). Figure 3.1 gives an 
overview of the principle of the [35S]GTPγS assay. 
 
 
 
Figure 3.1. G protein activation/deactivation cycle 
after GPCR stimulation by an agonist (Hill et al., 
2001); adapted from (Seifert and Wieland, 2005). 
Agonist binding to G protein-coupled receptors 
stimulates the exchange of GTP for GDP bound 
to the α subunit of coupled heterotrimeric GTP 
binding proteins. This causes the dissociation of 
the complex into the GPCR, the GTP- or 
[35S]GTPyS-bound Gα-subunit and the Gβγ-
dimer. The G protein subunits each activate 
effector proteins until the nucleotide is cleaved 
into GDP and inorganic phosphate (Pi) by 
GTPase. In the [35S]GTPyS assay, the non-
hydrolyzable GTP analog [35S]GTPyS dissociates 
slowly from the Gα protein, so it accumulates. 
Association of GDP-bound Gα with the Gβγ-dimer 
is the termination of the cycle. 
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Hence, a [35S]GTPγS assay for the hY2R and the hY4R (Dautzenberg et al., 2005) was 
established by analogy with the strategies described for other class A GPCRs heterologously 
expressed in Sf9 cells (Schneider and Seifert, 2010; Wieland and Seifert, 2006). Sf9 insect 
cells provide an excellent background due the absence of endogenous constitutively active 
receptors (Schneider and Seifert, 2010; Wieland and Seifert, 2006), making them suitable for 
investigations on constitutive GPCR activity. In contrast to the GTPase assay, there is no 
amplification of the signal in the [35S]GTPγS assay. Functional activities of selected agonists 
and antagonists (see section 1.2.1) at the hY2R were compared to results from GTPase (Pop 
et al., 2011) and calcium mobilization assays (Pluym, 2011; Shoblock et al., 2009). At the 
hY4R the endogenous ligand hPP, [Lys4]hPP and GW1229 were investigated and the effect 
of different sodium concentrations on receptor activation was studied. 
 
3.2 Material and methods 
3.2.1 Materials 
The constructs of the human pVL1392-SF-Y2R-His6 and pVL1392-SF-Y4R-His6 vector were 
provided by Dr. N. Pop (Pop et al., 2011). The recombinant baculovirus encoding the Gαi2 
subunit was kindly provided by Dr. A. G. Gilman (Department of Pharmacology, University of 
Southwestern Medical Centre, Dallas, TX USA), and the recombinant baculovirus encoding 
the unmodified version of the Gβ1γ2 subunits was a kind gift of Dr. P. Gierschik (Department 
of Pharmacology and Toxicology, University of Ulm, Ulm, Germany). BaculoGOLD 
transfection kit was from PharMingen (San Diego, CA). The peptides pNPY, hPP and 
[Lys4]hPP were synthesized by Synpeptide (Shanghai, China). GW1229 (also designated 
GR231118 or 1229U91) was a gift from Dr. A. J. Daniels, Glaxo Wellcome Inc., USA. JNJ-
31020028 (UR-KK54) (Shoblock et al., 2009) and [³H]UR-KK200 (Kuhn et al., 2016) were 
synthesized by K. Kuhn (University of Regensburg, Germany), pNPY 22-36 was synthesized 
by Dr. M. Kaske (University of Regensburg, Germany). BIIE0246 (Doods et al., 1999) and 
UR-PLN75 were synthesized by Dr. Nikola Pluym in our research group as part of a doctoral 
project (Pluym, 2011). The chemical structures of the ligands are depicted in section 1.2.1. 
Peptides (1 mM) were dissolved in 10 mM HCl. BIIE0246 (10 mM), UR-PLN75 (10 mM) and 
JNJ-31020028 (10 mM) were dissolved in DMSO. Dilutions were prepared in binding buffer 
(75 mM Tris/HCl, 12.5 mM MgCl2, 1 mM EDTA, pH 7.4).The amount of DMSO was adjusted 
to a final concentration of 2% in all assays. Coated reaction vessels (Sigmacote, Sigma 
Aldrich, Deisenhofen, Germany) were used for peptides. [35S]GTPγS (≥ 1000 Ci/mmol, 
radiochemical purity > 95%) was from Hartmann Analytic (Braunschweig, Germany). All 
other reagents were from standard suppliers and of the highest purity available. 
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3.2.2 Cell culture, generation of recombinant baculoviruses, Sf9 cell 
membrane preparation 
Cell culture and generation of high-titre recombinant baculovirus stocks as well as the co-
infection of Sf9 cells with high-titre baculovirus stocks encoding Gαi2, Gβ1γ2, and the hY2R or 
the hY4R were performed as described by Pop et al, 2011. Membrane preparations were 
performed according to Seifert et al. (1998) in the presence of 0.2 mM phenylmethylsulfonyl 
fluoride, 1 mM ethylenediaminetetraacetic acid (EDTA), 10 μg/mL leupeptin and 10 μg/mL 
benzamidine as protease inhibitors. Prepared membranes were re-suspended in binding 
buffer (75 mM Tris/HCl, 12.5 mM MgCl2, 1 mM EDTA, pH 7.4) and stored at -80 °C in 0.5 or 
1.0 mL aliquots.  
 
3.2.3 [35S]GTPγS binding assay at the hY2R and the hY4R 
Membranes were thawed, centrifuged at 4 °C and 13,000 g for 10 min and carefully re-
suspended in binding buffer. Experiments were performed in PrimariaTM 96-well plates 
(Corning Life Sciences, Oneonta, NY) in a total volume of 100 μL per well. Each well 
contained 6-15 μg of protein, reaction buffer (binding buffer with 1 μM GDP, 0.05% (w/v) 
bovine serum albumin (BSA), 20 nCi of [35S]GTPγS (0.2 nM)) and the ligand (10-fold 
concentrated) at concentrations as indicated in the results section. In the antagonist mode at 
the hY2R, test compounds were incubated in the presence of pNPY (final concentration: 
18 nM) at a final concentration of 2% DMSO. Nonspecific binding was determined in the 
presence of 10 μM unlabeled GTPγS. For optimization of the incubation period, membranes 
were incubated with [35S]GTPγS in the presence (1 µM) and absence of pNPY in binding 
buffer containing 2% DMSO for 15, 30, 45, 60, 90 and 120 min. After incubation under 
shaking at 200 rpm at room temperature, bound [35S]GTPγS was separated from free 
[35S]GTPγS by filtration through glass microfibre filters using a 96-well Brandel harvester 
(Brandel Inc., Unterföhring, Germany). After three washing steps with binding buffer, for each 
well filter pieces were punched out and transferred into 96-well sample plates 1450-401 
(Perkin Elmer, Rodgau, Germany). Each well was supplemented with 200 μL of scintillation 
cocktail (Rotiscint Eco plus, Roth, Karlsruhe, Germany) and incubated in the dark under 
shaking at 200 rpm. Radioactivity was measured with a Micro Beta2 1450 scintillation 
counter. At least two independent experiments (in triplicate) were performed and 
experiments were analyzed by four-parameter sigmoidal fits (GraphPad Prism 5.0, San 
Diego, CA). EC50, Kb and α were calculated as means ± SEM. The maximal response to 
pNPY (hY2R) and hPP (hY4R), respectively, was set to 100% in the agonist mode. In the 
antagonist mode (hY2R), the inhibition was referred to the response to pNPY (18 nM) in the 
presence of BIIE0246. To optimize the signal-to-noise ratio at the hY4R, the effects of NaCl 
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(0, 50, 100, 150 mM) and MgCl2 (1, 12.5, 20 mM) at different concentrations were 
investigated. 
 
3.2.4 Radioligand binding at hY4R Sf9 membranes 
The experiments were performed in PrimariaTM 96-well plates (Corning Life Sciences). Each 
well contained 60 μg of protein in a total volume of 200 μL. For saturation binding, 
membranes were incubated in buffer I (25 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2, pH 7.4) 
containing [³H]UR-KK200 (0.15 - 5 nM) and 1% (w/v) BSA for 90 min at room temperature 
under shaking at 200 rpm. Nonspecific binding was determined in the presence of a 100-fold 
excess of [Lys4]hPP. Filtration through glass microfibre filters (Whatman GF/C), pretreated 
with polyethylenimine 0.3% (w/v), using a Brandel 96 sample harvester separated unbound 
from membrane-associated [³H]UR-KK200. After three washing steps with binding buffer for 
each well filter pieces were punched out and transferred into 96-well sample plates 1450-401 
(Perkin Elmer). Each well was supplemented with 200 μL of scintillation cocktail (Rotiscint 
Eco plus) and incubated in the dark under shaking at 200 rpm. Radioactivity (dpm) was 
measured with a Micro Beta2 1450 scintillation counter.  
Specific binding data from saturation experiments was plotted against the ‘free’ radioligand 
concentration and analyzed according to a two-parameter hyperbolic curve fit (Binding – 
Saturation: One site – Specific binding, GraphPad Prism 5.0). 
 
3.3 Results and discussion 
3.3.1 [35S]GTPγS binding assay at the hY2R 
Monitoring the time course of [35S]GTPγS binding in the presence and absence of pNPY, 
respectively, a plateau of bound [35S]GTPγS in the presence of pNPY was reached after 
90 min with a signal-to-noise ratio of approximately 3. Upon stimulation with pNPY, exchange 
of non-hydrolyzable [35S]GTPγS (instead of GTP) for GDP at the Gα subunit occurs (Figure 
3.2). 
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Figure 3.2. Representative time course of 
[35S]GTPγS binding in the presence and absence 
of pNPY (1 µM). Two independent experiments 
were performed in triplicate. 
 
Potencies (EC50) and maximal effects (α) as well as antagonist activities (Kb) at the hY2R in 
the [35S]GTPγS-assay were determined by using selected agonists and antagonists, 
respectively (Figure 3.3 and Table 3.1). In literature, Dautzenberg et al. performed the 
[35S]GTPγS-assay with membrane preparations of HEK293 cells expressing the hY1, hY2, 
hY4 and mY5R, respectively, and several ligands were tested at all subtypes (i.e. hY2R: 
EC50(hNPY) = 29 nM; EC50(NPY3-36) = 61 nM; EC50(NPY13-36) = 95 nM) (Dautzenberg et 
al., 2005). In the [35S]GTPγS-assay performed with Sf9 membranes, the potency of pNPY 
was in good agreement with the EC50 values determined in a calcium mobilization assay and 
in the GTPase assay (Table 3.1). When tested in the agonist mode, antagonists such as the 
hY2R standard antagonist BIIE0246 showed no inverse agonism. Therefore these ligands 
were tested in the antagonist mode. BIIE0246 and its acylguanidine analog UR-PLN75 
behaved as full antagonists and the Kb values were in good agreement with reported data 
(Table 3.1). In literature, JNJ-31020028 is reported as a high affinity hY2R antagonist with a 
Kb value of 9.1 nM determined in a calcium mobilization assay (Shoblock et al., 2009). 
Functional studies in the [35S]GTPγS assay confirmed the antagonism of JNJ-31020028 at 
the hY2R, and the determined Kb value of 10.0 nM was in good agreement with the published 
data. Except for UR-PLN75, radioligand binding data were in the same range as the 
respective Kb values from functional studies in the [35S]GTPγS assay (Table 3.1).  
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Figure 3.3. Concentration-response curves of agonists (A) and antagonists (B) investigated in the 
[35S]GTPγS assay at the hY2R. (A) In the agonist mode, the effect of pNPY22-36 is referred to the 
maximal response elicited by pNPY. (B) Antagonists were investigated versus pNPY (18 nM) as the 
agonist; maximal inhibition was determined in the presence of BIIE0246. Data represent mean 
values ± SEM from at least two independent experiments performed in triplicate. 
 
Table 3.1. NPY hY2R agonist potencies (EC50) and intrinsic activities (α), antagonistic 
activities (Kb) of selected compounds. 
 
 
[35S]GTPγS assay  Reference data 
Compound     EC50 or (Kb) [nM]a α EC50 or (Kb) [nM] Ki [nM]
f 
pNPY    9.9 ± 1.1 1.00 
 
 11.7 ± 3.0b 
 
1.72 ± 0.13 
    16.9 ± 2.5c  
pNPY22-36     42 ± 5 0.99   n.d. 12.5 ± 1.8 
BIIE0246   (5.5 ± 1.4) - (10.2 ± 1.8)b    24 ± 3 
     (5.6 ± 0.4)d  
UR-PLN75    (3.3 ± 0.8) -   (2.1 ± 0.4)d    31 ± 2 
JNJ-31020028 (10.0 ± 2.6) -   (9.1 ± 0.7)e    30 ± 2 
[a] [35S]GTPγS functional binding assays with membrane preparations of Sf9 cells expressing the 
hY2R + Gαi2 + Gβ1γ2 + RGS4; the intrinsic activity (α) of pNPY was set to 1.00 and α values of other 
compounds were referred to this value in the agonist mode; the Kb values of antagonists were 
determined in the antagonist mode versus pNPY (18 nM) as the agonist; Kb values were calculated 
according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973); mean values ± SEM (n = 2-3). 
[b] steady-state GTPase assay; data reported by Pop et al. 2011. [c-e] [Ca2+]i mobilization in hY2R-
expressing cells; [c] (Ziemek et al., 2006); [d] (Pluym, 2011);.[e] (Shoblock et al., 2009). [f] hY2R 
binding determined by displacement of [3H]propionyl-pNPY (1 nM) from CHO cells, stably expressing 
the hY2R; mean values ± SEM (n = 3-4).  
 
 
3.3.2 [35S]GTPγS binding assay at the hY4R 
Previously, membrane preparations (batch B75) of Sf9 cells expressing the hY4R were 
successfully applied to establish a steady state GTPase assay (Pop et al., 2011). Therefore, 
the applicability to a [35S]GTPγS assay was explored. Unfortunately, it was not possible to 
determine EC50 values of hPP as the response of the activated hY4R almost equals the 
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bound [35S]GTPγS in the absence of agonist. Therefore, new recombinant viruses encoding 
the hY4 receptor were generated using the BaculoGOLD transfection kit according to the 
manufacture’s protocol (Sf9 membranes, batch B171). The membranes were subjected to 
saturation binding experiments with [³H]UR-KK200 to confirm the hY4R expression 
(Figure 3.4). The radioligand [³H]UR-KK200 was selected because this compound was 
characterized at CHO hY4R cells to specifically bind to the hY4R with a Kd value of 0.67 nM 
(Kuhn et al., 2016). Saturation binding of [³H]UR-KK200 at the first batch of Sf9 membranes 
(B75) revealed a Kd value of 1.78 ± 0.04 nM which is in good agreement with experiments 
performed with CHO hY4R cells (Figure 3.4A). Saturation binding experiments at the second 
batch of membranes (B171) failed (Figure 3.4B). Regardless of that, effort was spent to 
optimize the [35S]GTPγS assay protocol using membrane batches B75 and B171.  
 
 
Figure 3.4. Saturation analysis of different membrane preparations of Sf9 insect cells expressing the 
hY4R. (A) Representative saturation binding experiment with membrane batch B75 (n = 3); Kd = 1.78 
± 0.04 nM. (B) Binding experiment with membrane batch B171 (n = 2). 
 
Mg2+ ions critically influence G protein function (Birnbaumer et al., 1990) and are 
indispensable for [35S]GTPγS binding. Mg2+ ions increase the basal [35S]GTPγS binding, but 
in particular enhance the signal upon agonist stimulation of a GPCR. Comparable 
concentration-response curves of hPP at the hY4R were obtained in the presence of 
12.5 mM (reported assay condition) and 20 mM MgCl2, whereas a concentration of 1 mM 
MgCl2 was obviously too low (Figure 3.5).  
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Figure 3.5. Representative concentration–
response curves of hPP in the presence of 1, 
12.5 and 20 mM MgCl2; means ± SEM, assay 
performed in triplicate (n = 2). 
As reported in literature, Na+ acts as an allosteric inverse agonist at several Gi/o-coupled 
GPCRs and stabilizes the inactive state of the receptors (Schnell et al., 2010; Seifert and 
Wenzel-Seifert, 2001; 2002). The presence of Na+ ions improves the agonist stimulated 
binding of [35S]GTPγS relative to basal binding and hence the signal-to-noise ratio (Lazareno 
and Birdsall, 1993; Selley et al., 2000; Szekeres and Traynor, 1997; Tian et al., 1994). Na+ 
ions are thought to bind to a conserved aspartate residue in transmembrane II of GPCRs 
(Horstman et al., 1990) and this facilitates uncoupling of the receptor-G protein complex and 
a decrease in basal [35S]GTPγS binding. Therefore, concentration-response curves of the 
agonist hPP were performed in the presence of Na+ ions at increasing concentrations (Figure 
3.6A). Sodium induced a decrease in basal [35S]GTPγS binding and a lower potency (EC50) 
of hPP which was also reported for the GTPase assay (Pop et al., 2011). A decrease in the 
basal [35S]GTPγS binding by 50% and of the maximum response by 30% was observed in 
the presence of 50 mM NaCl compared to the absence of NaCl. This is in good agreement 
with data determined in the GTPase assay at the hY4R where the suppression of basal 
GTPase activity by 50 mM NaCl amounted to 47% (Pop et al., 2011). The signal-to-noise 
ratio was further improved to approximately 2:1 at higher NaCl concentrations. Furthermore, 
EC50 values of the agonists [Lys4]hPP and GW1229 were determined in the presence 
(50 mM) and absence of NaCl for comparison with the effects of NaCl observed in the 
GTPase assay (Pop et al., 2011). Interestingly, for these ligands a lower potency by a factor 
of 4 ([Lys4]hPP) and 3 (GW1229) was determined in the presence of 50 mM NaCl in the 
[35S]GTPγS assay (Figure 3.6B, Table 3.2). Compared to the EC50 values in the GTPase 
assay, the activity of hPP was 19-fold lower and [Lys4]hPP revealed 331 nM versus 143 nM. 
Most pronounced decrease in potency was observed for GW1229, which was 81- and 180-
fold lower than reported for the GTPase assay in the absence and presence of NaCl 
(50 mM). The obvious discrepancies, including the rank order of the potencies of ligands, 
comparing [35S]GTPγS and GTPase assay, are difficult to explain as in both cases receptor-
mediated activation is measured at the G-protein level. Although a certain difference in the 
potency of agonists may be expected due to signal amplification in the GTPase assay, the 
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robustness of the data gained from the [35S]GTPγS appears questionable. Functional studies 
at the hH4R resulted in comparable pEC50 values of tested ligands such as histamine, 
thioperamide and UR-PI294 (Nordemann et al., 2013). One possible explanation could be 
the different composition of the used buffers which may result in a lower potencies especially 
at peptidergic GPCRs such as the hY4R (see chapter 5; (Kuhn et al., 2016)).  
  
Figure 3.6. Selected ligands investigated in the [35S]GTPγS assay at the hY4R. (A) Representative 
concentration-response curves of hPP in the presence of 0 (●), 50 (◊), 100 (▲) and 150 (□) mM 
NaCl (n = 3). (B) Concentration-response curves of GW1229 and [Lys4]hPP in the absence (solid 
line) and in the presence of 50 mM NaCl (dashed line). All curves are scaled with respect to a 
maximal hPP effect of 100%. Data represent mean values ± SEM; three independent experiments 
were performed in triplicate. 
 
Table 3.2. hY4R agonist potencies (EC50) and intrinsic activities (α) of selected peptides and 
reference compound hPP, in the absence and presence of NaCl. 
 
                                               [35S]GTPγS binding assay  steady-state GTPase assay 
Compound EC50 [nM]a α  EC50 [nM]b  α 
hPP   206 ± 30 1.00 
 
 11.0 ± 3.6 
 
1.00 
    4.5 ± 0.8c    
hPP + 50 mM NaCl   182 ± 38 1.00 
 
 28.3 ± 5.3 1.00 
hPP + 100 mM NaCl   240 ± 3 1.00 
 
  n.d.  
hPP + 150 mM NaCl    367 ± 11 1.00 
 
  n.d.  
[Lys4]hPP   331 ± 34 0.95  143 ± 24 1.02 
[Lys4]hPP + 50 mM NaCl 1230 ± 206 0.96    n.d.  
GW1229     99 ± 20 1.19 0.55 ± 0.15  0.82 
GW1229 + 50 mM NaCl   334 ± 29 1.20   4.1 ± 0.2 0.97 
[a] [35S]GTPγS functional binding assays with membrane preparations of Sf9 cells expressing the 
hY4R + Gαi2 + Gβ1γ2 +RGS4; the intrinsic activity (α) of hPP was set to 1.00 and α values of other 
compounds were referred to this value; mean values ± SEM (n = 3-4). [b] steady-state GTPase assay 
on membrane preparations expressing the hY4R + Gαi2 + Gβ1γ2 + RGS4; data reported by Pop et al. 
2011. [c] Data reported by Dautzenberg et al. 2005; [35S]GTPγS assay with membrane preparations of 
HEK293 cells expressing the hY4R. 
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3.4 Summary and conclusion 
The baculovirus/Sf9 cell system is appropriate for the functional characterization of hY2R 
ligands in the [35S]GTPγS binding. Pharmacological data of reference compounds 
determined in this assay were in good agreement with functional studies in the steady-state 
GTPase assay and the calcium mobilization assay at the hY2R. 
The [35S]GTPγS assay at the hY4R revealed potencies of hPP and GW1229, which were 
lower by a factor 19 and 180, respectively, compared to reported data for the steady-state 
GTPase assay. Increasing Na+ concentrations led to minor changes of the potency of hPP in 
the [35S]GTPγS assay, whereas [Lys4]hPP and GW1229 were markedly less potent in the 
presence of sodium. This is in agreement with the data from radioligand binding assays at 
the hY4R (see section 5.3.3; (Kuhn et al., 2016)). Nevertheless, the [35S]GTPγS assay is 
compromised by a low signal-to-noise ratio impairing the robustness of the data. 
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4 Development of luminescence based 
reporter gene assays for the human 
neuropeptide Y2 and Y4 receptor 
  
34 4.1 Introduction 
4.1 Introduction 
Because of their simplicity reporter gene assays are in widespread use for the study of ligand 
activity and potency and a convenient method for the measurement of functional response to 
Gαs, Gαi/o and Gαq coupled GPCRs (Tang et al., 2004). A variety of reporters under control of 
specific responsive elements are in use for different classes of receptor and allow the 
quantification of agonist and antagonistic activity in living cells or cell lysates (Hill et al., 
2001). Reporter gene assays are based on the modulation of transcription factors by GPCR 
signaling. The enhanced or repressed transcription of the gene is caused by the binding of 
these factors to regulatory elements in the promoter region of a target. The Y2R and Y4R 
couple to Gαi/o G-proteins, which mediate inhibition of the adenylyl cyclase (AC), resulting in 
a decrease in cAMP formation. Hence, the cAMP response element (CRE) has been 
preferably used. For the purpose of detection of a negative regulation of the AC, a 
stimulation of the AC is required to raise the cAMP level. This is accomplished by using the 
diterpene forskolin (see Figure 4.1) (Seamon and Daly, 1981). 
 
                                               Figure 4.1. Chemical structure of the diterpene forskolin. 
 
 
 
A scheme is given in Figure 4.2A which shows the Y2R and Y4R signaling pathway where a 
CRE-linked reporter gene is involved. Activation by an agonist of the respective receptor 
decreases forskolin stimulated luciferase activity, reflecting the inhibitory quality of the Gαi/o 
protein. Inverse agonists cause a shift of constitutively active receptors to an inactive 
conformation resulting in a decrease of the (constitutive) inhibition of the AC and in an 
increase in forskolin stimulated luciferase activity (see Figure 4.2B). Kb values of neutral 
antagonists are determined in the antagonist mode upon stimulation of the receptor by the 
respective agonist. 
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Figure 4.2. Schematic illustration of a CRE-controlled reporter gene assay (A). Activation of the Gi/o 
coupled Y2R and Y4R by agonists implicates inhibition of the AC and, consequently, a decrease in 
transcription, whereas inverse agonists cause an increase in transcription. Neutral antagonists do not 
change the forskolin-stimulated luciferase activity. Forskolin-induced luciferase activity in cells in the 
presence and absence of agonist, inverse agonist and neutral antagonist (B). 
 
In literature, the luciferase reporter gene assay in HEK293 cells was described for the human 
neuropeptide Y5R (Beauverger et al., 2005). Functional activity of ligands at the Y2R and Y4R 
has been determined, for example, in the steady-state GTPase activity assay (Pop et al., 
2011) and Ca2+ mobilization assay such as the aequorin and fura-2 assay (Ziemek et al., 
2006; Ziemek et al., 2007). 
The aim of this work was to develop a CRE-directed luciferase reporter gene assay in 
HEK293T cells, stably expressing the hY2R or the hY4R. Reporter gene assays provide a 
distal readout characterized by signal amplification. This may lead to increased agonist 
efficacy compared to more proximal readouts (George et al., 1997). Therefore, as far as 
possible, the data determined for a set of Y2R and Y4R ligands (for structures cf. section 1.2) 
in the luciferase assays were compared with results from functional assays on Sf9 cell 
membranes, such as the GTPase activity (Pop et al., 2011) or the [35S]GTPγS binding assay 
(cf.chapter 3), and the arrestin recruitment assay for the hY4R (cf. section 5.3.2). The 
potency of forskolin was determined to optimize assay sensitivity since the required 
concentration of forskolin for pre-stimulation depends on the cell type (Williams, 2004). 
Incubation periods of at least 4 – 6 h are indispensable taking into consideration the time 
course of transcription and translation. However, the risk of agonist mediated receptor 
desensitization raises with the duration of exposure, and this may result in a decrease in 
agonist potencies (Hill et al., 2001). In order to find the minimum incubation period required 
for appropriate signal strength, the time course of the luciferase reporter gene expression 
was determined. As peptidic (endogenous) ligands can be degraded by proteases under 
assay conditions, the stability of selected ligands and the effect of the protease inhibitor 
Gβγ
AC
ATP cAMP
PKA
CREB
CRE
reporter gene
Gαi/o
agonist forskolinA B
-9 -8 -7 -6 -5 -4
full agonist
antagonist
"full" inverse agonist
in
c
re
a
s
e
d
e
c
re
a
s
e
c
o
n
tr
o
l
forskolin
Log c (ligand, M)
C
h
a
n
g
e
 i
n
 f
o
rs
k
o
li
n
-
s
ti
m
u
la
te
d
 l
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
36 4.2 Materials and methods 
bacitracin were investigated as well. As shown in Figure 4.3, the luciferase enzyme from the 
American firefly Photinus pyralis catalyzes in a multistep reaction the formation of oxyluciferin 
from the natural substrate D-luciferin, accompanied by emission of yellow/green light 
(560 nm). After injection of D-luciferin light is emitted, the intensity of which decreases during 
several seconds and reaches a plateau. The luciferase reaction is achieving a high signal-to-
noise ratio, as cells or cell lysates normally do not emit interfering light (Bronstein et al., 
1994; Shinde et al., 2006). 
 
Figure 4.3. Conversion of D-luciferin by firefly luciferase to oxyluciferin (according to (Shinde et al., 
2006)). 
 
 
4.2 Materials and methods 
4.2.1 Stable transfection of HEK293T-hY2-CRE Luc and HEK293T-hY4-CRE 
Luc cells with the pGL4.29[luc2P/CRE/Hygro] vector 
HEK293T cells were stably co-transfected with the pGL4.29[luc2P/CRE/Hygro] plasmid 
(Promega, Mannheim, Germany) encoding hygromycin B resistance and the firefly 
luciferase, the transcription of which is controlled by the Camp responsive element 
(HEK293T-CRE Luc cells; (Nordemann et al., 2013)), and pcDNA3.1 hY2 vector or pcDNA3.1 
hY4 vector (cDNA Resource Center; Bloomsberg, PA, USA), encoding the hY2R (HEK293T-
hY2-CRE Luc cells) and hY4R (HEK293T-hY4-CRE Luc cells), respectively, and neomycin 
resistance. For transfection, the cells were seeded into a 24 well-plate (Becton Dickinson, 
Heidelberg, Germany), so that they reached 60–70% confluency on the next day. The 
transfection mixture containing 2 μg of the DNA and 8 μL of FuGene HD transfection reagent 
(Roche Diagnostics, Mannheim, Germany) was prepared according to the manufacturer’s 
protocol and added to the cells, followed by an incubation period of 48 h at 37 °C and 5% 
CO2 in a water-saturated atmosphere.  
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4.2.2 Cell culture 
HEK293T–CRE-Luc cells stably expressing either the hY2R or the hY4R were cultured in 
Dulbecco`s Modified Eagle Medium (DMEM) (Sigma-Aldrich, Deisenhofen, Germany) 
containing L-glutamine (Sigma-Aldrich), 4500 mg/L glucose, 3.7 g/L NaHCO3 (Merck, 
Darmstadt, Germany), 110 mg/L sodium pyruvate (Serva, Heidelberg, Germany), 10% fetal 
calf serum (FCS) (Biochrom, Berlin, Germany) and the selection antibiotics G418 
(600 μg/mL) (Biochrom) and hygromycin b (300 μg/mL) (MoBiTec, Göttingen, Germany). 
Cells were maintained in culture flasks from Sarstedt (Nümbrecht, Germany) at 37 °C in 
water saturated atmosphere containing 5% CO2 and diluted twice a week 1:10 with fresh 
medium after treatment with 0.05% trypsin / 0.02% EDTA (PAA, Pasching, Austria). The 10-
fold concentrate of trypsin/EDTA was diluted with phosphate buffered saline (KCl 2.7 mM; 
KH2PO4 1.5 mM; NaCl 137 mM; Na2HPO4 5.6 mM; NaH2PO4 1.1 mM in Millipore water, 
pH 7.4, all chemicals were from Merck). 
 
4.2.3 Saturation binding on HEK293T-CRE-Luc hY2R and HEK293T-CRE-Luc 
hY4R cells 
For saturation binding experiments at HEK293T-CRE-Luc hY2R cells, cells were grown to 
80% - 100% confluency, detached from the culture flask and centrifuged at 300 g for 5 min. 
The culture medium was discarded, and the cells were re-suspended at a density of 
106 cells/mL in buffer I (25 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2, pH 7.4) supplemented 
with 1% BSA and 0.1 mg/mL bacitracin. Experiments were performed in a final volume of 
200 μL in PrimariaTM 96-well plates (Corning Life Sciences, Oneonta, NY) in a concentration 
range of 0.25 - 20 nM with the radioligand [³H]propionyl pNPY. Nonspecific binding was 
determined in the presence of a 150-fold excess of pNPY. Incubation period was 90 min. 
Bound and free radioligand were separated by filtration through 0.3% polyethyleneimine pre-
treated GF/C filters (Whatman, Maidstone, UK) using a Brandel Harvester (Brandel, 
Gaithersburg, MD, USA). Filter pieces for each well were punched out and transferred into 
96- well plates 1450-401 (PerkinElmer) and scintillation cocktail (200 μL, Rotiscint eco plus) 
was added. After incubation in the dark for 60 min, radioactivity (dpm) was measured with a 
MicroBeta2 plate counter (PerkinElmer). 
The radioligand [³H]UR-KK200 (Kuhn et al., 2016) was used for saturation binding 
experiments at intact HEK293T-hY4-CRE Luc cells. Experiments were performed in a 
concentration range of 0.15 – 5 nM and nonspecific binding was determined in the presence 
of a 100-fold excess of [Lys4, Nle17,30]hPP. Experiments were performed as described above. 
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4.2.4 Luciferase reporter gene assay  
4.2.4.1 Preparation of stock solutions and dilution series  
Forskolin stock solution was prepared in 100% DMSO. Dilutions for concentration-response 
curves of forskolin were freshly made in DMEM without phenol red and 10% DMSO. The 
peptides pNPY, hPP, [Lys4]hPP, [Lys4, Nle17,30]hPP, [Lys4,Met(O)17,30]hPP, [Lys4,Met(O2)17,30] 
were synthesized by Synpeptide (Shanghai, China). JNJ-31020028 (UR-KK54) (Shoblock et 
al., 2010) was synthesized by K. Kuhn, pNPY 22-36 and M3 were synthesized by Dr. M. 
Kaske (University of Regensburg, Germany). The peptides pNPY2-36 and BW1911U90 were 
kindly provided by Prof. Dr. C. Cabrele (University of Salzburg, Austria). BIIE0246 (Doods et 
al., 1999), UR-PLN187 and UR-PLN208 were synthesized by Dr. Nikola Pluym in our 
research group as part of his doctoral project (Pluym, 2011). GW1229 (also designated 
GR231118 or 1229U91) was a gift from Dr. A. J. Daniels, Glaxo Wellcome Inc., USA. UR-
MK188 was synthesized by Dr. M. Keller (Keller et al., 2013). For the synthesis of propionyl-
[Lys4]hPP, propionyl-[Lys4,Nle17,30]hPP and S0223[Lys4,Nle17,30]hPP cf. chapter 5. The 
chemical structures of the ligands are depicted in section 1.2.1. Peptides (1 mM) were 
dissolved in 10 mM HCl. BIIE0246 (10 mM), UR-PLN187 (10 mM), UR-PLN208 (10 mM), 
JNJ-31020028 (10 mM) and UR-MK188 (10 mM) were dissolved in DMSO. Dilution series of 
the compounds were prepared in DMEM without phenol red and 0.5% BSA. The amount of 
DMSO was adjusted to a final concentration of 0.2% in all assays performing the antagonist 
mode and 0.02% performing the agonist mode. Coated reaction vessels were used for 
peptides (Sigmacote, Sigma-Aldrich).  
 
4.2.4.2 Preparation of the cells and determination of bioluminescence 
The luciferase assay was performed on HEK293T-hY2-CRE Luc cells and HEK293T-hY4-
CRE Luc cells, respectively. One day prior to the experiment, the cells were adjusted to a 
density of approximately 800,000 per mL in DMEM without phenol red supplemented with 
5% FCS. Cells were seeded in a volume of 160 μL per well into PrimariaTM 96-well plates 
and allowed to attach at 37 °C, 5% CO2 in a water-saturated atmosphere overnight. A stock 
solution (10 mM) of forskolin (Sigma) in DMSO was used to prepare feed solutions in DMEM 
without phenol red (final DMSO concentration in the assay was 0.02% in the agonist mode 
and 0.2% in the antagonist mode, respectively). After addition of 20 μL of forskolin solution 
(final concentration 2 μM), 20 μL of a 10-fold concentrated solution of the respective test 
compound were added in the agonist mode. For assays performed in the antagonist mode, 
the forskolin solution was supplemented with 15 nM of pNPY (final concentration 1.5 nM) at 
the Y2R and with 22 nM of [Lys4, Nle17,30]hPP (final concentration 2.2 nM) at the Y4R, 
respectively. The cells were incubated at 37 °C in water saturated atmosphere containing 5% 
 Chapter 4 39 
CO2 for 4.5 h. Afterwards, the medium was discarded, and 80 μL of lysis solution (25 mM 
Tricine, 10% (v/v) Glycerol, 2 mM EGTA, 1% (v/v) TritonTM X-100, 5 mM MgSO4 · 7 H2O, 
1 mM DTT; pH 7.8) were added to each well. The plates were shaken at 600 rpm for 30 min. 
Afterwards, 40 μL of the lysate were transferred into white 96-well plates (Greiner, 
Frickenhausen, Germany). Luminescence was measured with a GENios Pro microplate 
reader. Light emission was induced by injecting 80 μL of the luciferase assay buffer (25 mM 
Gly-Gly; 15 mM MgSO4 · 7 H2O; 15 mM KH2PO4; 4 mM EGTA; 2 mM ATP disodium salt; 
2 mM DTT; 0.2 mg/mL D-luciferin potassium salt (Synchem, Felsberg, Germany); pH was 
adjusted to 7.8 with hydrochloric acid). Luminescence [RLU] was measured for 10 s. All data 
are presented as means ± SEM from at least two independent experiments performed in 
triplicate. Concentration-response curves from the luciferase assay were analyzed by four 
parameter sigmoidal fits (GraphPad Prism 5.0, San Diego, CA). Agonist potencies are given 
as EC50 values, maximal responses (efficacies) are expressed as α value referred to the 
effect of 300 nM pNPY (α = 1.0) or 300 nM hPP (α = 1.0), respectively. Antagonist activities 
are given as Kb values.  
 
4.2.4.3 Effect of the solvent on luciferase activity 
The stock solution of forskolin (10 mM) was prepared in DMSO or DMF, respectively. A 
volume of 20 μL of a forskolin solution (final concentration: 2 μM) and DMSO or DMF in a 
volume of 20 µL were added at increasing concentrations to 160 µL of cell culture medium 
per well. Luciferase assay was performed as described above. 
 
4.2.4.4 Determination of the optimal forskolin concentration 
A volume of 20 μL of a 10-fold concentrated forskolin solution (containing 10% DMSO) was 
added to 180 μL of cell culture medium per well. The cells were incubated for 4.5 h at 37 °C 
and 5% CO2 in a water saturated atmosphere. Forskolin was investigated at concentrations 
up to 100 μM to determine the optimal concentration. For measurement of luminescence cf. 
4.2.4.2. 
 
4.2.4.5 Effects of different forskolin concentrations on the concentration-response 
curves of pNPY and [Lys4, Nle17,30]hPP 
A volume of 20 μL of forskolin solution (final concentration 1 μM, 1.5 µM, 2 µM, 3 µM, 4 µM) 
and 20 μL of a 10-fold concentrated solution of pNPY and [Lys4, Nle17,30]hPP, respectively, 
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were added to 160 μL of cell culture medium per well, and the assay was performed as 
described above. 
 
4.2.4.6 Effect of bacitracin on the stability of pNPY and [Lys4, Nle17,30]hPP 
The stock solution of bacitracin (100 mg/mL) was prepared in water. For a final concentration 
of 0.1 mg/mL in the assay, bacitracin was added to the forskolin solution 10-fold 
concentrated. Luciferase assay was performed as described above. EC50 values of pNPY 
and [Lys4, Nle17,30]hPP were determined in the absence and in the presence of bacitracin 
(0.1 mg/mL).  
 
4.2.4.7 Monitoring the time course of luciferase expression 
A forskolin solution (20 µL, 20 μM) was added to 180 μL of cell culture medium per well. The 
luminescence was measured after 0.0, 1.0, 2.0, 3.0, 4.0, 5.0, 4.5, 5.0, 8.0, 9.0, 22 and 23 h. 
The basal luminescence was subtracted from each signal and the obtained values were 
plotted against the time. 
 
4.2.4.8 Control experiments using HEK293T-CRE-Luc cells devoid of hY2R and 
hY4R 
The procedure was the same as described in section 4.2.4.2, but HEK293T-CRE-Luc cells 
devoid of hY2R and hY4R, respectively, were used. All RLUs were referred to the luciferase 
activity at 2 μM forskolin which was used for pre-stimulation and set to 100%.  
 
4.3 Results and discussion 
 
4.3.1 Reporter gene assay for the human neuropeptide Y2 receptor 
4.3.1.1 Saturation binding assay using HEK293T-hY2-CRE Luc cells 
Due to the poor adherence of the HEK293T cells (Lieb et al., 2016), the assay was 
performed by using cells in suspension. The bound radioligand [³H]propionyl-pNPY was 
separated from the free radioligand by filtration. Unfortunately, the nonspecific binding was 
high, and binding was not saturable (Figure 4.4). The hY2R expression could not be 
confirmed by saturation binding assays. 
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Figure 4.4. Representative binding experiment 
on HEK293T-CRE-Luc hY2R cells. Nonspecific 
binding of [3H]prop.-pNPY was determined in 
the presence of a 150-fold excess of pNPY. Two 
independent experiments were performed in 
triplicate. 
  
4.3.1.2 Effects of the solvent on the luciferase activity 
The effects of DMSO and DMF (Figure 4.5) on the luciferase signal were investigated, as 
DMSO can negatively effect bioluminescence (Plank, 2016).  
 
 
Figure 4.5. Impact of DMSO and DMF on the 
luciferase signal. Cells were incubated with 
buffer containing the respective solvent. The 
luciferase activity induced by 2 µM forskolin was 
set to 100%. Data are means ± SEM of three 
independent experiments, each performed in 
triplicate. 
DMSO at a concentration of 1.1% reduced the maximum luciferase signal by approximately 
58%, whereas in the presence of 2.5% DMSO the signal was almost completely suppressed. 
The effect of DMF was investigated as an alternative to DMSO. Interestingly, at a final 
concentration of 0.6% DMF the reduction of the luminescence signal was comparable to a 
DMSO concentration of 1.1%. In the presence of 1.6% DMF the signal was almost 
completely suppressed. Therefore, DMSO should not be replaced by DMF as solvent, if the 
concentration of these solvents exceeds the standard value of 0.2%. 
 
4.3.1.3 Optimization of stimulation with forskolin 
In literature, the concentration of forskolin used in reporter gene assays for Gαi/o coupled 
GPCRs ranges from 500 nM (Kemp et al., 1999) to 10 μM (Liu et al., 2001). HEK293T-hY2-
CRE Luc cells were incubated with increasing forskolin concentrations in 1% DMSO or 
1% DMF, respectively (Figure 4.6). In a concentration dependent manner, forskolin 
stimulated luciferase expression up to a concentration of 10 μM. Higher forskolin 
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concentrations caused a decrease in luciferase expression as already described for several 
cell types expressing the luciferase gene reporter (George et al., 1997; Kemp et al., 2002; 
Stroop et al., 1995). All respective dilutions were freshly prepared for every assay to exclude 
precipitation of forskolin. 
 
 
Figure 4.6. Forskolin-stimulated luciferase 
expression in HEK293T-hY2-CRE Luc cells. 
“Bell-shaped” concentration-response curve 
in 1% DMSO and 1% DMF. Data represent 
mean values ± SEM of at least three 
independent experiments performed in 
triplicate. 
The “bell-shaped” concentration-response curve showed a maximum at 10 µM of forskolin. 
Hence, only the ascending part of the curve was considered for the determination of the EC50 
value of forskolin (2 µM). The decrease in luciferase expression at higher concentrations of 
forskolin may be interpreted as a hint to endogenous cAMP dependent ICER activity in 
HEK293T cells which was shown for CHO cells (Kemp et al., 2002). Stimulation with 2 µM of 
forskolin turned out to be suitable to perform the reporter gene assay with HEK293T-hY2-
CRE Luc cells. 
 
4.3.1.4 Optimization of the period of incubation  
According to the literature, the preferred incubation period for luciferase reporter gene 
assays ranges from 4 h (Kemp et al., 1999) to 8 h (Li et al., 2007). For optimization of the 
assay, the time course of the luciferase expression in HEK293T-hY2-CRE Luc cells was 
investigated. Luciferase gene transcription was stimulated with 2 μM of forskolin, and the 
cells were lysed after various incubation periods as shown in Figure 4.7. The maximum of 
expression was reached after a period of 9 h, after 23 h the luciferase activity amounted to 
46% of the maximal response. An incubation period of 4.5 h appeared to be sufficient, as 
74% of the maximum expression were reached.  
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Figure 4.7. Time course of luciferase 
expression in HEK293T-hY2-CRE Luc cells 
after stimulation with 2 μM of forskolin. 
Luciferase activity was determined after the 
indicated incubation periods (mean values ± 
SEM; n = 2). 
 
4.3.1.5 Effects of different forskolin concentrations on pNPY concentration-response 
curves 
Concentration-response curves of pNPY in the presence of different forskolin concentrations 
revealed comparable EC50 values (0.17 – 0.41 nM). As shown in Figure 4.8, the amplitude of 
the concentration-response curves (903,000 - 1,012,000 RLU) remains nearly unchanged 
with increasing forskolin concentrations. 
 
 
Figure 4.8. Representative 
concentration-response curves of 
pNPY in the presence of different 
forskolin concentrations. Data 
represent means ± SEM (performed 
in triplicate). 
 
 
 
4.3.1.6 Effect of bacitracin on the stability of pNPY 
Bacitracin, an antibiotic containing a mixture of related cyclic peptides, is also known as 
protease inhibitor and commonly used in peptide research (Wang and Adrian, 1995). As 
enzymatic cleavage under assay conditions cannot be precluded, concentration-response 
curves of the peptide pNPY were constructed in the absence and presence of bacitracin 
(0.1 mg/mL) (Figure 4.9). Surprisingly, the curves and the determined EC50 values were 
identical, that is, pNPY was stable under these assay conditions and bacitracin can be 
omitted.  
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Figure 4.9. Concentration-response curves of 
pNPY at HEK293T-hY2-CRE Luc cells in the 
absence (■) and presence (□) of bacitracin 
(0.1 mg/mL). Data are means ± SEM of a 
representative experiment performed in 
triplicate. 
  
4.3.1.7 Control experiments on cells devoid of the hY2R  
In principle, changes in CRE-controlled luciferase activity can be caused by off-target effects 
independent of the GPCR of interest (Atwood et al., 2011). Therefore, control experiments 
with HEK293T-CRE-Luc cells devoid of the hY2R were performed. The cells were stimulated 
with 2 μM forskolin and co-incubated with the agonist pNPY or the antagonist BIIE0246 
(Figure 4.10). Changes in luciferase activity were not detected, that is, the effects depicted in 
Figure 4.11 are Y2R-mediated.  
 
 
Figure 4.10. Luciferase activity in the 
presence of the agonist pNPY (final c(DMSO) 
= 0.02%) and the antagonist BIIE0246 (final 
c(DMSO) = 0.2%) in the reporter gene assay 
using HEK293T-CRE Luc cells devoid of Y2R 
expression. Data are means ± SEM of a 
representative experiment performed in 
triplicate. 
  
4.3.1.8 Functional activities of selected ligands at the hY2R 
Selected ligands including agonists and antagonists (cf. section 1.2.1), were investigated for 
their ability to change forskolin (2 µM) stimulated luciferase activity in HEK293T-hY2-CRE 
Luc cells. All antagonists behaved as neutral antagonists in the agonist mode (data not 
shown). The determined EC50 values or Kb values were compared, as far as possible, with 
results from functional studies using more proximal readouts in G-protein mediated signal 
transduction, e.g. the functional [35S]GTPγS binding assay (cf. chapter 3) and the steady-
state GTPase activity assay (Pop et al., 2011), which were both performed on membrane 
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preparations of Sf9 cells expressing the hY2R. The obtained results as well as the reported 
data are summarized in Table 4.1. NPY and its analogs pNPY2-36 and pNPY22-36 acted as 
full agonists on HEK293T-hY2-CRE Luc cells (Figure 4.11A, Table 4.1). The EC50 values of 
these agonists were in the same range as reported binding data, determined in a radioligand 
binding assay with [³H]propionyl-pNPY (Table 4.1). Although the EC50 values were lower 
compared to EC50 values from other functional assays, the rank order of potencies and 
affinities (pNPY > pNPY2-36 > pNPY22-36) was identical (Table 4.1). In the antagonist 
mode, BIIE0246 antagonized the pNPY induced decrease in luciferase activity with a Kb 
value of 1.08 nM, which was lower compared to the results determined in the GTPase and 
[35S]GTPγS assay (cf. section 3.3.1). In agreement with data from the Ca2+ mobilization and 
the [35S]GTPγS binding assay, the derivatives of BIIE0246, namely UR- PLN187 and UR-
PLN208, proved to be full antagonists.  
 
 
Figure 4.11. Concentration-response curves of pNPY, pNPY2-36, pNPY22-36, BIIE0246, UR-
PLN187, UR-PLN208 and JNJ-31020028 in the luciferase assay on HEK293T-hY2-CRE Luc cells. (A) 
Agonist mode, maximum change of 1 is defined as full agonism and referred to the effect of pNPY 
(α = 1.0). (B) Antagonist mode, maximum change is defined as full antagonism and referred to the 
effect of 1 µM BIIE0246. Data points shown are the mean values ± SEM of at least three independent 
experiments performed in triplicate. 
 
In summary, agonistic and antagonistic activities at the hY2R were determined on genetically 
engineered HEK293T cells (HEK293T-hY2-CRE Luc cells) co-expressing the hY2R and a 
CRE controlled luciferase reporter gene. The agonistic potencies of the investigated Y2R 
ligands were in accordance with the Ki values determined in radioligand binding studies. 
Except for UR-PLN208, all antagonists showed higher activities compared to functional 
studies in other assays. In case of agonists, it should be kept in mind that potential 
differences may be masked in assays with a distal readout due to signal amplification in the 
second messenger cascade downstream from G-protein activation. 
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Table 4.1. NPY hY2R agonist potencies (EC50), intrinsic activities (α) and affinities of selected 
peptides and reference compound pNPY. 
Compound 
 
EC50 [nM] 
or (Kb) [nM]a 
α 
 
 EC50 [nM]  
 or (Kb) [nM] 
 
 Ki [nM]i 
pNPY 0.58 ± 0.07 1.0 
 
 
  11.7 ± 3.0b 
 
 1.72 ± 0.13 
     16.9 ± 2.5d  
pNPY2-36   3.7 ± 0.4 1.07    n.d.    5.8 ± 1.1 
     
pNPY22-36 18.0 ± 2.3 0.99      42 ± 5h  12.5 ± 1.8 
      
BIIE0246 (1.0 ± 0.1) 
 
 (10.2 ± 1.8)b  24.4 ± 3 
     (5.6 ± 0.4)e   
UR-PLN187 (3.0 ± 0.1) 
 
   (6.8 ± 1.9)f    101 ± 13 
    
UR-PLN208  (7.9 ± 1.9) 
 
   (8.2 ± 0.4)e   19.5 ± 3.7 
     (8.3 ± 0.5)c  
JNJ-31020028 (1.9 ± 0.3) 
 
 (10.0 ± 2.6)h  29.8 ± 2.2 
     (9.1 ± 0.7)g  
[a] CRE-luciferase reporter gene assay on HEK293T cells stably expressing the hY2R. Y2R agonist 
potency was determined from the inhibition of forskolin (2 μM) stimulated luciferase activity; in the 
agonist mode, the intrinsic activity (α) of pNPY was set to 1.0 and α values of other compounds were 
referred to this value; maximum change of 1 indicates full agonism; the Kb values of neutral 
antagonists were determined in the antagonist mode versus pNPY (1.5 nM) as the agonist; Kb values 
were calculated according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973); mean values ± 
SEM, at least three independent experiments were performed in triplicate. [b-c] Steady-state GTPase 
assay on membrane preparations expressing the hY2R + Gαi2 + Gβ1γ2 + RGS4; [b] data reported by 
(Pop et al., 2011); [c] (Baumeister, 2014). [d-g] Calcium mobilization assay on CHO cells, stably 
expressing the hY2R; [d] data reported by (Ziemek, 2006); [e] (Pluym et al., 2013); [f] (Pluym, 2011); 
[g](Shoblock et al., 2010). [h] [35S]GTPγS functional binding assay with membrane preparations of Sf9 
cells expressing the hY2R + Gαi2 + Gβ1γ2 +RGS4 (see section 3.3.1). [i] Radioligand binding assay 
performed with [³H]prop.-NPY (c = 1 nM) at CHO hY2R cells; mean values ± SEM, at least three 
independent experiments were performed in triplicate. 
 
4.3.2 Reporter gene assay for the human neuropeptide Y4 receptor 
4.3.2.1 Saturation binding assay using HEK293T-hY4-CRE Luc cells 
Receptor expression was confirmed by saturation binding assays using whole cells. The 
quantitative analysis of the saturation binding of [3H]UR-KK200 resulted in around 100,000 
receptors per cell for the HEK293T-hY4-CRE Luc cells (Figure 4.12). The determined Kd 
value of 0.48 ± 0.13 nM was in the same range as data determined on CHO cells, stably 
expressing the hY4R (0.67 nM; (Kuhn et al., 2016)).  
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Figure 4.12. Representative saturation binding 
experiment with [3H]UR-KK200 on HEK293T-
CRE-Luc hY4R cells. Nonspecific binding was 
determined in the presence of a 100-fold excess 
of [Lys4, Nle17,30]hPP; Kd = 0.48 ± 0.13 nM; 
experiment performed in triplicate. 
 
4.3.2.2 Effect of the solvent on the luciferase activity 
The effects of DMSO and DMF were investigated as described for the hY2R (section 4.3.1.2, 
Figure 4.13).  
 
 
Figure 4.13. Impact of DMSO and DMF on the 
luciferase signal. Cells were incubated with 
buffer containing the respective solvent. The 
luciferase activity induced by 2 µM forskolin 
(0.02% DMSO or 0.02% DMF) was set to 
100%. Data are means ± SEM of three 
independent experiments, each performed in 
triplicate. 
 
 
DMSO at a concentration of 1.1% reduced the maximum luciferase signal by approximately 
53%, whereas in the presence of 2.5% DMSO the signal was almost completely suppressed. 
The effect of DMF was investigated with respect to a possible alternative to DMSO. 
Reduction of the maximum luminescence signal is comparable to results for the hY2R (see 
section 4.3.1.2). Therefore, DMSO should not be replaced by DMF as solvent, if the 
concentration exceeds the standard value of 0.2%. 
 
4.3.2.3 Optimization of stimulation with forskolin 
HEK293T-hY4-CRE Luc cells were incubated with increasing forskolin (FSK) concentrations 
in the presence of 1% DMSO or 1% DMF (Figure 4.14). In a concentration dependent 
manner, forskolin stimulated luciferase expression up to a concentration of 10 μM.  
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Figure 4.14. Forskolin-stimulated luciferase 
expression in HEK293T-hY4-CRE Luc cells. 
“Bell-shaped” concentration-response curve 
in the presence of 1% DMSO and 1% DMF. 
Data points are mean values ± SEM of at 
least three independent experiments 
performed in triplicate. 
 
The “bell-shaped” concentration-response curve showed a maximum at 10 µM (1% DMSO) 
and 30 µM (1% DMF) of forskolin, respectively. Hence, the ascending part of the curve was 
considered for the determination of the EC50 value (2 µM in the presence of DMSO) of 
forskolin. The low level of the luciferase activity in 1% DMF is also shown in section 4.3.2.2. 
 
4.3.2.4 Optimization of the incubation time 
For optimization of the assay conditions, the time course of the luciferase expression in 
HEK293T-hY2-CRE Luc cells was investigated. Luciferase gene transcription was stimulated 
with 2 μM of forskolin, and the cells were lysed after various incubation periods as shown in 
Figure 4.15. Maximum expression was reached after a period of 9 h. The signal decreased to 
47% after 23 h. Therefore, an incubation period of 4.5 h, when 73% of the maximum 
expression were reached, appeared to be sufficient. 
 
 
Figure 4.15. Time course of luciferase 
expression in HEK293T-hY4-CRE Luc cells 
after stimulation with 2 μM of forskolin. 
Luciferase activity was determined after the 
indicated incubation periods (mean values ± 
SEM; n = 2). 
  
 
4.3.2.5 Effects of different forskolin concentrations on the concentration-response 
curve of [Lys4, Nle17,30]hPP 
Concentration-response curves of [Lys4, Nle17,30]hPP in the presence of different forskolin 
concentrations revealed comparable EC50 values (0.24 — 0.96 nM). As shown for 
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representative experiments in Figure 4.16 the amplitude of luciferase activity was almost the 
same (2,260,000 – 2,850,000 RLU) irrespective of increasing forskolin concentrations.  
 
 
4.16. Representative concentration-response 
curves of [Lys4, Nle17,30]hPP in the presence of 
different forskolin (FSK) concentrations. Data 
represent means ± SEM (performed in 
triplicate). 
  
4.3.2.6 Effect of bacitracin on the stability of [Lys4, Nle17,30]hPP 
As also described above for pNPY at the hY2R (cf. section 4.3.1.6), no effect of bacitracin 
was observed in case of [Lys4, Nle17,30]hPP (Figure 4.17). Hence, [Lys4, Nle17,30]hPP is stable 
under these assay conditions and bacitracin can be omitted. 
 
 
Figure 4.17. Concentration-response curves 
of [Lys4, Nle17,30]hPP at HEK293T-hY4-CRE 
Luc cells in the absence (■) and presence (□) 
of bacitracin (0.1 mg/mL). Data are means ± 
SEM of representative experiments, each 
performed in triplicate. 
  
4.3.2.7 Control experiments on cells devoid of the hY4R  
In control experiments, HEK293T-CRE-Luc cells devoid of the hY4R were stimulated with 
2 μM forskolin and co-incubated with the agonist hPP (see Figure 4.18). Changes in 
luciferase activity were not detected, confirming that the effects of the investigated Y4R 
ligands shown in Figure 4.19 are receptor mediated.  
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Figure 4.18. Luciferase activity in the reporter 
gene assay at HEK293T-CRE Luc cells 
devoid of the Y4R using hPP as agonist. 
Stimulation with forskolin (2 μM). Data are 
means ± SEM of a representative experiment 
performed in triplicate. 
4.3.2.8 Functional activities of selected ligands at the hY4R 
Selected ligands including agonists and antagonists (for structures cf. sections 1.2.2 and 5.1) 
were investigated for their ability to change forskolin (2 µM) stimulated luciferase activity in 
HEK293T-hY4-CRE Luc cells. The determined EC50 values or Kb values were compared, as 
far as possible, with results from functional studies using more proximal readouts, e.g. the 
arrestin recruitment assay on HEK293T-ARRB1-Y4R and HEK293T-ARRB2-Y4R cells 
(T.Littmann, personal communication), and the steady-state [33P]GTPase activity assay (Pop, 
2011), which was performed on membrane preparations of Sf9 cells expressing the hY4R. 
The obtained results as well as the reported data are summarized in Table 4.2. 
The peptide hPP and its analogs [Lys4]hPP and [Lys4, Nle17,30]hPP acted as full agonists on 
HEK293T-hY4-CRE Luc cells (Figure 4.19). The potencies of these agonists were in 
accordance with reported binding data, determined in a radioligand binding assay with 
[³H]propionyl-[Lys4, Nle17,30]hPP in buffer I (25 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2, 
pH 7.4) (see section 5.3.5). Although, the EC50 values were lower compared to the Ki values 
and EC50 values of other functional assays such as the arrestin recruitment assay, the rank 
order of potencies and affinities (hPP > [Lys4, Nle17,30]hPP > [Lys4]hPP) was identical, which 
is in agreement with binding and functional data from different assays. In literature, GW1229 
was reported both as a partial (Berglund et al., 2003b; Ziemek et al., 2007) and a full agonist 
(Berglund et al., 2003a; Parker et al., 1998). Interestingly, in the luciferase assay GW1229 
was a full agonist and nearly 100 times more potent (EC50 = 5.5 nM) than in the β-arrestin-1 
recruitment assay (EC50 = 413 nM). The replacement of Arg25 in the Y4R partial agonist 
[cpen34]pNPY(25-36) by a functionalized arginine building block resulted in the ligand M3 
(Ac-Arg(Nω-Ahx)-HYINLITR-cpen-RY-NH2) which was investigated in our working group 
(Kaske, 2012). M3 acted as partial agonist at the hY4R which was in agreement with results 
from the GTPase activity assay (Kaske, 2012). In case of BW1911U90, there are 
discrepancies regarding the intrinsic activity in different assays. Whereas BW1911U90 acted 
as a full agonist in the GTPase assay (Pop et al., 2011) and the cAMP assay (Parker et al., 
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1998), the hY4R was only partially activated in the luciferase reporter gene assay (α = 0.51). 
UR-MK188 antagonized the [Lys4, Nle17,30]hPP induced decrease in luciferase activity. The 
determined Kb value of 30 nM was in good agreement with results from the Ca2+ mobilization 
assay (Kb = 20 nM; (Keller et al., 2013).  
 
 
Figure 4.19. Potencies and efficacies of hPP, 
M3 and BW1911U90 in HEK293T-hY4-CRE Luc 
cells. Agonist mode, maximum change is 
referred to the maximal response to hPP 
(α = 1.0). Data points shown are the mean 
values ± SEM of at least three independent 
experiments, each performed in triplicate. 
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Table 4.2. NPY hY4R agonist potencies (EC50) and intrinsic activities (α) of selected 
peptides and reference compound hPP. 
Compound 
 
   EC50 [nM] 
or (Kb) [nM]a 
α 
 
   EC50 [nM]d 
 or (Kb) [nM] 
α 
 
β-arrestin 
isoform 
hPP  0.6 ± 0.1a 1.0 
 
 
  4.4 ± 0.02 
 
1.0 1 
     3.1 ± 0.01 1.0 2 
[Lys4]hPP  1.5 ± 0.2a 0.99   7.3 ± 0.03 0.75 1 
     5.0 ± 0.03 0.88 2 
Propionyl-[Lys4]hPP  3.5 ± 0.4a 0.97    15 ± 0.08 0.81 1 
      10 ± 0.04 0.89 2 
[Lys4,Met(O)17,30]hPP  4.2 ± 0.3a 1.02    42 ± 0.18 0.72 1 
      27 ± 0.12 0.79 2 
[Lys4,Met(O2)17,30]hPP  1.9 ± 0.4a 0.99    10 ± 0.05 0.71 1 
     6.4 ± 0.02 0.80 2 
[Lys4,Nle17,30]hPP   0.9 ± 0.1a 1.00    15 ± 0.05 0.74 1 
      10 ± 0.03 0.86 2 
Prop.-[Lys4,Nle17,30]hPP  1.0 ± 0.1a 0.99    14 ± 0.09 0.79 1 
     9.2 ± 0.04 0.83 2 
S0223[Lys4,Nle17,30]hPP  3.1 ± 0.9a 1.00    19 ± 0.12 0.84 1 
      13 ± 0.10 0.89 2 
GW1229  5.5 ± 0.8a 1.01  413 ± 2 0.53 1 
    236 ± 2 0.63 2 
 
BW1911U90 107 ± 13a 0.51 n.d.   
  8.9 ± 1.5b 1.28    
M3 130 ± 17a 0.77 n.d.   
   38 ± 8.8b 0.67    
UR-MK188  (30 ± 2.4)a 
 
   55 ± 22  1 
    (46 ± 18)  2 
[a] CRE-luciferase reporter gene assay on HEK293T cells stably co-expressing the hY4R and the 
CRE-controlled luciferase gene reporter. Y4R agonist potency was determined from the inhibition of 
forskolin (2 μM) stimulated luciferase activity; the intrinsic activity (α) of hPP was set to 1.00 and α 
values of other compounds were referred to this value, maximum change of 1 indicates full agonism; 
the Kb values of neutral antagonists were determined in the antagonist mode versus [Lys4,Nle17,30]hPP 
(2.2 nM) as the agonist; Kb values were calculated according to the Cheng-Prusoff equation (Cheng 
and Prusoff, 1973); mean values ± SEM (n = 3 - 9). [b-c] Steady-state GTPase assay on membrane 
preparations expressing the hY4R + Gαi2 + Gβ1γ2 + RGS4; [b] data reported by Pop et al. (Pop et al., 
2011); [c] data reported by (Kaske, 2012). [d] Arrestin recruitment assay on HEK293T-ARRB1-Y4R 
and HEK293T-ARRB2-Y4R cells (see section 5.3.2; T. Littmann, personal communication). The 
maximal response (intrinsic activity, α) is referred to the effect of hPP set to α =  1.0; Kb value of UR-
MK188 was determined in the antagonist mode versus hPP (3 nM) as the agonist and calculated 
according to the Chen-Prusoff equation; data represent mean values ± SEM from at least two 
independent experiments performed in triplicate.  
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In summary, agonistic and antagonistic activities at the hY4R were determined on genetically 
engineered HEK293T cells (HEK293T-hY4-CRE Luc cells) co-expressing the hY4R and a 
CRE controlled luciferase reporter gene. Activation of hY4R in the luciferase assay resulted in 
higher agonist potencies compared to functional assays providing more proximal readouts 
such as the GTPase or the -arrestin recruitment assay. This may be interpreted as a hint to 
signal amplification. Ki values determined in radioligand binding studies in buffer I were in 
good agreement with the EC50 values determined in the luciferase assay. 
 
4.4 Summary and conclusion 
Agonistic and antagonistic activity can be determined in HEK293T cells, stably expressing 
the human Y2 and Y4 receptor, respectively, by using a CRE-controlled luciferase reporter 
gene assay. Non-Y2R and -Y4R mediated (off-target) effects were not detected in cells of the 
same genetic background, that is, HEK293T-CRE-Luc cells devoid of Y2R or Y4R. An optimal 
incubation period of 4.5 h was determined by monitoring the time course of the luciferase 
expression which was nearly identical for the Y2R and Y4R expressing cells. A ‘bell-shaped’ 
concentration-response curve of forskolin became obvious, presumably, caused by activation 
of ICER at high cAMP concentrations. The optimum concentration of 2 µM of forskolin was 
used throughout in the luciferase assay. As the concentration-response curves of peptide 
agonists remained unchanged in the presence of bacitracin, the addition of a protease 
inhibitor appears unnecessary. Furthermore, a tremendous impact of solvents on luciferase 
activity became obvious by investigating DMSO and DMF as possible solvents for water-
insoluble compounds. DMSO should be preferred to DMF, however, at the concentrations 
required to keep forskolin and test compounds in solution, the inhibitory solvent effect was 
negligible. The determined potencies of selected Y2R and Y4R ligands at the respective 
receptor were generally higher compared to data determined in other functional assays. 
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5 Fluorescence- and radiolabeling of 
[Lys4,Nle17,30]hPP yields molecular tools 
for the NPY Y4 receptor  
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5.1 Introduction 
The neuropeptide Y (NPY) family comprises the 36-amino acid peptides neuropeptide Y 
(NPY), peptide YY (PYY), and pancreatic polypeptide (PP). In humans, the biological effects 
of these peptides are mediated by four functionally expressed receptor subtypes, designated 
Y1, Y2, Y4 and Y5 receptors (Y1R, Y2R, Y4R, Y5R) (Zhang et al., 2011). Among the NPY 
receptors the Y4R is unique, as it prefers PP over NPY and PYY as the endogenous ligand. 
PP is predominantly expressed in an endocrine cell type (PP cells) of the pancreas (Wang et 
al., 2013), and is, for example, considered to be involved in satiety signaling, the regulation 
of food intake and energy metabolism. Therefore, Y4R agonists are discussed as potential 
anti-obesity drugs (Kamiji and Inui, 2007; Li et al., 2010; Yulyaningsih et al., 2011). For the 
characterization of Y4R ligands, pharmacological tools are indispensable. Affinity data are 
usually determined in radioligand binding assays using membranes or homogenates of Y4R 
expressing cells and [125I]-labeled rPP (Walker et al., 1997; Yan et al., 1996), hPP (3) 
(Berglund et al., 2001; Eriksson et al., 1998; Parker et al., 2002; Parker et al., 2005), 
GR231118 (syn. GW1229) (4) (Dumont and Quirion, 2000) PYY (Dautzenberg et al., 2005), 
or [Leu31,Pro34]PYY (Gehlert et al., 1997) (Figure 5.1) as tracers, which are obtained by 
iodination of tyrosine residues. An alternative to [125I]-labeling is [3H]propionylation of a non-
essential primary amino group in analogs of appropriate peptides or non-peptides containing, 
e. g., lysine or “arginysine”, an amino-functionalized arginine-derived building block (Keller et 
al., 2016). Dimeric analogs of the C-terminal pentapeptide of PP, previously identified as 
potent Y4R agonists (Balasubramaniam et al., 2006), were recently structurally optimized to 
obtain [3H]-labeled and fluorescent tools (Kuhn et al., 2016; Liu et al., 2016a; Liu et al., 
2016b). 
In principle, labeling of the -amino group in lysine is a convenient way to synthesize 
structurally uniform radioligands as well as fluorescent derivatives of the same precursor. 
Porcine NPY (2) (pNPY), which differs from the human peptide by a Leu residue instead of 
Met in position 17 and is comparable to hNPY (1) regarding affinity and potency, is usually 
preferred due to higher chemical stability (Clark et al., 1987; Martel et al., 1990). Previously 
described cyanine-labeled pNPY and [Lys4]hPP (7) enabled flow cytometric binding assays 
under equilibrium conditions on the Y1R (Schneider et al., 2006), and the Y4R (Ziemek et al., 
2007), respectively. By analogy with tritium-labeling of pNPY (Keller et al., 2015), a 
corresponding tritiated Y4R ligand should be easily accessible and useful to complement the 
arsenal of molecular tools. Unfortunately, during storage in buffer, oxidation of the 
methionine residues in 7 and derivatives was detected by HPLC-MS analysis. Aiming at 
more stable full length labeled hPP analogs, we selected [Lys4,Nle17,30]hPP (11) as a 
template, as the methionine residues in position 17 and 30 in 7 are prone to oxidation 
(Scheme 5.1). For comparison, we included the oxidized analogs of 7, [Lys4,Met(O)17,30]hPP 
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(9) and [Lys4,Met(O2)17,30]hPP (10), in the present study because the impact of the sulfoxide 
and sulfone groups on biological activity and binding at the Y4R was unknown. [3H]propionyl-
[Lys4]hPP ([³H]8), [³H]propionyl-[Lys4,Nle17,30]hPP ([³H]12) and the cyanine-labeled 
fluorescent peptide S0223[Lys4,Nle17,30]hPP (13) (Scheme 5.1) were synthesized and 
characterized in saturation and kinetic Y4R binding experiments, in functional studies and 
with respect to NPY receptor subtype selectivity. The labeled compounds were also used to 
determine the affinities of unlabeled compounds in competition binding assays.  
 
Figure 5.1. Amino acid sequences of the peptide agonists hNPY (1), pNPY (2), hPP (3) and structures 
of the Y1R antagonist/Y4R agonist GW1229 (4), the radiolabeled Y4R agonist [³H]UR-KK193 ([3H]5), 
and the Y1R/Y4R antagonist UR-MK188 (6). Amino acids in pNPY and hPP which differ from the hNPY 
sequence are highlighted in blue. 
 
Previously, experiments performed with the radioligand [3H]UR-KK193 ([3H]5, Figure 5.1) 
(Kuhn et al., 2016) in different buffers revealed that the discrepancies between binding data 
are, at least in part, caused by the absence or presence of sodium ions. A ‘sodium effect’ in 
agonist binding was also described for other GPCRs such as the adenosine and the δ-opioid 
receptor (Liu et al., 2012). Therefore, special attention was paid to the influence of the 
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sodium ion concentration and isotonic vs. hypotonic conditions on the hY4R binding 
characteristics of the labeled and unlabeled ligands.  
 
Scheme 5.1. Structures of [Lys4]hPP (7), [Lys4,Nle17,30]hPP (11), oxidation products and 
derivatives obtained by conjugation at Lys4 with tritiated or unlabeled propionic acid or 
fluorescent dye. 
 
5.2 Materials and methods 
5.2.1 General experimental conditions 
Chemicals and solvents were from commercial suppliers and used without further purification 
unless otherwise indicated. Na2CO3, NaHCO3 for buffer preparation and acetonitrile (MeCN) 
for HPLC (gradient grade) were from Merck (Darmstadt, Germany). DMF for peptide 
synthesis was from Acros Organics/Fisher Scientific (Nidderau, Germany). The succinimidyl 
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ester (S0223-NHS) of the fluorescent dye S2197 was from FEW Chemicals (Bitterfeld-
Wolfen, Germany). Glycine was from Thermo Fisher Scientific (Darmstadt, Germany), 
trifluoroacetic acid (TFA), ethanol, Sigmacote and Triton X-100 were from Sigma-Aldrich 
(Deisenhofen, Germany), N,N-diisopropylethylamine (DIPEA) (99%) was from ABCR 
(Karlsruhe, Germany). Bovine serum albumin (BSA) and bacitracin were from Serva 
(Heidelberg, Germany). Human pancreatic polypeptide (hPP), 7, 11 and porcine 
neuropeptide Y (pNPY) were synthesized by solid-phase peptide synthesis (SPPS). 
Chemicals for SPPS: Nα-Fmoc amino acids (side-chain protecting groups: tBu for Thr, Tyr, 
Asp, Glu; Trt for Asn and Gln; Boc for Lys; Pbf for Arg), DMF, 1-methyl-2-pyrrolidinone 
(NMP), dichloromethane (DCM), diethyl ether (Et2O), and DIPEA were from Iris Biotech 
GmbH (Marktredwitz, Germany). The Fmoc-Rink amide MBHA resin (0.45 mmol/g) was from 
Novabiochem (Merck Millipore Darmstadt, Germany). 1-Hydroxybenzotriazole (HOBt), 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU), TFA and 
piperidine were obtained from Biosolve (Valkenswaard, The Netherlands). All chemicals and 
solvents were of peptide-synthesis grade. Triisopropylsilane (TIS), 1,2-ethanedithiol (EDT) 
and thioanisole (TIA) were from Sigma-Aldrich. Compounds 9 and 10 were from Synpeptide 
(Shanghai, P.R. China). Naphthalene-1-sulfonic acid {trans-4-[(4-aminoquinazolin-2-
ylamino)methyl] cyclohexyl-methyl}amide (Criscione et al., 1998) was synthesized as 
described previously (Li et al., 2003). Compound 4 was a gift from Dr. A. J. Daniels (Glaxo 
Wellcome, NC, USA). The synthesis of compound 6 was previously described (Keller et al., 
2013). Stock solutions (1 mM) of the peptides were prepared with 10 mM HCl and stored at –
20 °C. The solids and stock solutions of hPP, 7-10 were stored under an argon atmosphere. 
Millipore water was used throughout for the preparation of buffers and HPLC eluents. 
Polypropylene reaction vessels (1.5 or 2 mL) with screw caps (Süd-Laborbedarf, Gauting, 
Germany) were used for the synthesis of the radioligands [3H]8, [3H]12 and [3H]propionyl-
pNPY, for small scale reactions (e.g. the preparation of the `cold´ analogs) and for the 
storage of stock solutions. Sigmacote was used for coating the polypropylene reaction 
vessels to prevent adsorption of the peptides. 
High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an ESI 
source. Preparative HPLC was performed on a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps and a K-2001 detector using mixtures of acetonitrile and 
0.1% aqueous TFA solution as mobile phase (flow rate 15 mL/min). A detection wavelength 
of 220 nm was used throughout. The collected fractions were lyophilized using an alpha 2-4 
LD apparatus (Martin Christ, Osterode am Harz, Germany) equipped with a RZ 6 rotary vane 
vacuum pump (vacuubrand, Wertheim, Germany). Analytical HPLC analysis of compounds 
12, 13 was performed with a system from Thermo Separation Products composed of a 
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SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, Phenomenex), an 
AS3000 autosampler and a SpectraFOCUS forward optical scanning detector. A YMC-Triart 
C 8 (250 x 4.6 mm, 5 μm; YMC Europe, Dinslaken, Germany) served as RP-column at a flow 
rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.05% aq TFA (B) were used as mobile 
phase. An injection volume of 100 μL and a detection wavelength of 220 nm (additionally 
630 nm for 13) were used throughout. Analytical HPLC analysis of ‘cold’ 8 was performed 
with a HPLC system from Waters (Eschborn, Germany) consisting of two 510 pumps, a 
pump control module, and a 486 UV/VIS detector. A Synergi Hydro-RP (250 x 4.6 mm, 4 μm; 
Phenomenex, Aschaffenburg, Germany) was used as stationary phase at a flow rate of 
0.8 mL/min. Solutions for injection (concentrations in the two-digit μM range) were prepared 
in a mixture of A and B corresponding to the composition of the eluent at the start of the 
gradient. 
 
5.2.2 Chemistry: experimental protocols and analytical data 
Compound 12 pentakis(hydrotrifluoroacetate). Compound 11 (2.8 mg, 0.68 μmol) was 
dissolved in 3% DIPEA in anhydrous DMF (80 μL). A solution of succinimidyl propionate in 
anhydrous DMF (1.4 mg/mL) was added in small portions (a total of 40 μL (0.34 μmol)). To 
prevent two-fold acylation, the reaction was monitored by HPLC. The mixture was acidified 
by addition of 10% aqueous TFA (14 μL). The product was purified by preparative HPLC 
(column: YMC-Actus-Triart C8 250 x 20 mm ID, S 5 µm,12 nm; gradient: MeCN/0.1% aq 
TFA: 0–21 min: 10:90 – 38:62, 21–40 min: 38:62 – 46:54, 40–48 min: 95:5. tR = 25.8 min). 
Lyophilisation of the eluate afforded 12 as a white fluffy solid (1.0 mg, 0.21 μmol). HRMS 
(m/z): [M+5H]5+ calcd. for C191H305N54O53, 840.6561; found, 840.6587. RP-HPLC (220 nm): 
99% (column: YMC-Triart C 8 (250 x 4.6 mm, 5 μm; gradient: MeCN/0.1% aq TFA: 0–30 min: 
15:85 – 42:58, 30–40 min: 95:5. tR = 26.9 min, k = 8.6). C191H300N54O53 · C10H5F15O10 
(4200.76 + 570.10). 
Synthesis of the radioligand [³H]12. A solution of succinimidyl [3H]propionate 
(500 µL = 2.5 mCi; 32 nmol; specific activity: 80 Ci/mmol (2.96 TBq/mmol), purchased from 
American Radiolabeled Chemicals, St. Louis, MO via Hartman Analytics, Braunschweig, 
Germany) in hexane/EtOAc (9:1) was transferred from the delivered ampoule into a 1.5 mL 
reaction vessel with screw cap, and the solvent was removed in a vacuum concentrator 
(30 °C, 30 min). A solution of 11 (0.5 mg, 109 nmol, in 0.1 M NaHCO3 (pH 9.2) containing 
35% DMF) (145 µL) was added, and the vessel was vigorously shaken at rt for 2 h. The 
mixture was acidified by addition of 2% aqueous TFA (87 μL) followed by addition of 
MeCN/H2O (10:90; 368 μL). [3H]12 was purified using a HPLC system from Waters 
(Eschborn, Germany) consisting of two 510 pumps, a pump control module, a 486 UV/VIS 
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detector and a Flow-one beta series A-500 radiodetector (Packard, Meriden, USA). A 
Synergi Hydro-RP (250 x 4.6 mm, 4 μm) was used as stationary phase at a flow rate of 
0.8 mL/min. Acetonitrile supplemented with 0.04% TFA (A) and 0.05% aq TFA (B) were used 
as mobile phase. The following linear gradient was applied: A/B: 0–25.5 min: 5:95 – 
40.5:59.5, 25.5–29 min: 40.5:59.5, 29–33 min: 40.5:59.5–46:54, 33–34 min: 46:54 – 95:5, 
34–42 min: 95:5. For the purification of the radiolabeled peptide four HPLC runs were 
performed. The radioligand was collected in 2-mL reaction vessels with screw caps, the 
volumes of the combined eluates were reduced by evaporation to 450 μL, and 50 µL of 
ethanol were added to obtain a solution containing 10% (v/v) ethanol for storage at 4 °C 
(stock solution). For the quantification of the radioligand [3H]12, two samples were prepared 
by diluting 2 µL of the radioligand solution with 128 μL MeCN/0.05% aq TFA (10:90). By five-
point calibration with 12 (0.1, 0.2, 0.35, 0.5 and 0.75 μM; injection volume: 100 μL, UV-
detection: 220 nm) a concentration of 8.13 μM of [3H]12 was determined in the stock by 
HPLC. The following linear gradient was applied: A/B: 0–30 min: 15:85 – 45:55, 30–39 min: 
95:5. To quantify the radioactivity, 3 μL of each sample were counted in 3 mL of liquid 
scintillator (Rotiszint eco plus, Carl Roth, Karlsruhe, Germany) with a LS 6500 liquid 
scintillation counter (Beckman Coulter, Krefeld, Germany) in pentuplicate. To determine the 
radiochemical purity and to prove the identity of the radioligand, a solution of the radiolabeled 
peptide (100 μL, 0.15 μM), spiked with ‘cold’ 12 (final concentration: 25 µM, tR = 29.3 min), 
was analyzed by HPLC with combined UV/radiochemical detection (Rotiszint eco 
plus/acetonitrile, 85:15 (v/v), flow rate: 4.0 mL/min). The radiochemical purity was 92%. 
Calculated specific activity: 41.42 Ci/mmol (1.532 TBq/mmol). Chemical yield: 
penta(hydrotrifluoroacetate) of [3H]12: 18.9 μg, 4.1 nmol, 12.8%. Radiochemical yield: 
0.168 mCi (6.22 MBq) in 500 µL, 6.7%. Analysis of the radioligand (100 μL, 0.10 μM) after 
storage at 4 °C for 7 months revealed a radiochemical purity of 88%. 
Synthesis of the fluorescent ligand 13. A solution of S2197 (S0223-NHS; 0.7 mg, 
1.06 μmol, 0.8 eq) in 30 µL DMF was added to a solution of 11 [1.53 mg, 0.33 μmol, 1 eq) in 
buffer (81.6% 0.5 M NaHCO3, 18.4% 0.5 M Na2CO3, pH 9.4) containing 23% DMF. After 
45 min a reaction control was performed by analytical HPLC, another portion (0.4 eq) of the 
active ester was added, and additional 1.5 eq were added after 30 and 60 min. The reaction 
was stopped by addition of 10% aq. TFA (40 μL) after a total incubation period of 3 h at room 
temperature. The product was purified by analytical HPLC (8 injections). Chemical yield: 13 
hexakis(hydrotrifluoroacetate): 0.96 mg, 0.206 μmol; RP-HPLC (220 nm): 96% (YMC-Triart 
C 8 (250 x 4.6 mm, 5 μm); gradient: MeCN 0.04% TFA/0.05% TFA: 0–30 min: A/B 20:80–
50:50, 30–31 min: 50:50–95:5, 31–40 min: 95:5; tR = 27.3 min, k = 8.8, 220 nm; tR = 27.7 min, 
630 nm); HRMS (m/z): [M+6H]6+ calcd. for C200H333N56O53, 768.7593; found, 768.7575. 
C200H333N56O53 · C12H6F18O12 (4610.34 + 684.12).  
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5.2.3 Fluorescence spectroscopy and determination of quantum yields  
Fluorescence quantum yields of 13 were determined in PBS (pH 7.4) and PBS containing 
1% BSA with a Cary Eclipse spectro-fluorimeter and a Cary 100 UV/VIS photometer (Varian 
Inc., Mulgrave, Victoria, Australia) according to a previously described procedure using acryl 
cuvettes (10 mm × 10 mm, Sarstedt, ref. 67.755) and cresyl violet perchlorate as quantum 
yield standard (Keller et al., 2011b). Emission spectra were recorded at the slit adjustments 
(ex./em.) 10/5 nm and 10/10 nm, and the quantum yields obtained for these slit combinations 
were averaged (cf. Supporting Information, Figure S9, Table S1). 
 
5.2.4 Investigation of the chemical stability of the peptides in buffer 
The chemical stability of hPP, 7, 8, 11, 12 and 13 was investigated in autoclaved buffer I at 
22 ± 1 °C. The incubation was started by addition of 9 μL (hPP, 7, 9, 10, 11) and 4.5 µL (8, 
12) of a 1 mM solution to the buffer (82 µL or 85.5 µL) to give final concentrations of 50 μM 
(hPP, 7-11) and 25 μM (8, 12), respectively. Compound 13 was dissolved in buffer I (100 µL) 
to give a final concentration of 40 µM. After 0, 4, 12 and 48 h, aliquots (20 μL) were taken, 
and 20 μL of MeCN/ 0.2% aq TFA (2:8 v/v) were added. Analytical HPLC analysis was 
performed with a system from Agilent Technologies composed of a 1290 Infinity binary pump 
equipped with a degasser, a 1290 Infinity autosampler, a 1290 Infinity thermostated column 
compartment, a 1260 Infinity diode array detector, and a 1260 Infinity fluorescence detector. 
A Kinetex-XB C18, 2.5 μm, 100 mm×3 mm (Phenomenex), served as stationary phase at a 
flow rate of 0.6 mL/min. Mixtures of acetonitrile (A) and 0.04% aq TFA (B) were used as 
mobile phase. The following linear gradients were applied. Compounds hPP, 7-12: 0–12 min: 
A/B 10:90 – 45:55, 12–16 min: 45:55– 95:5, 16–20 min: 95:5; 13: 0–12 min: A/B 10:90 – 
60:40, 12–16 min: 60:40– 95:5, 16–20 min: 95:5. The oven temperature was 25 °C, and the 
injection volume was 20 μL. Detection was performed at 220 nm throughout and additionally 
at 645 nm in case of 13. For chemical stabilities of hPP and 7-11 cf. Supporting Information 
Figures S3-S8. 
 
5.2.5 Cell culture  
The HEC-1B human endometrial cancer cell line and the MCF-7 (HTB 22) human breast 
cancer cells were from the American Type Culture Collection (Rockville, MD). A subclone of 
the MCF-7 cell line with high Y1R expression was established in our laboratory and used for 
binding experiments (Keller et al., 2011a). Human embryonal kidney cells (HEK-293T cells) 
and Chinese hamster ovarian (CHO) cells were from Deutsche Sammlung für 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). Routinely performed 
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examinations for mycoplasma contamination using the Venor GeM Mycoplasma Detection 
Kit (Minerva Biolabs, Berlin, Germany) were negative for all cell types.  
Cells were cultured in 25- or 75-cm2 flasks (Sarstedt, Nümbrecht, Germany) in a humidified 
atmosphere (95% air, 5% CO2) at 37 °C. MCF-7-Y1 cells,(Keller et al., 2011a) CHO-hY2-Gqi5-
mtAEQ cells (Ziemek et al., 2006) and CHO-hY4-Gqi5-mtAEQ cells (Ziemek et al., 2007), 
HEK293T-hY4-CRE Luc (Kuhn et al., 2016) cells and HEC-1B cells expressing the human 
Y5R (Moser, 2000) were cultured as previously described. 
 
5.2.6 Buffers used in binding and functional experiments  
Buffer I. A sodium-free, hypo-osmotic HEPES buffer (25 mM HEPES, 2.5 mM CaCl2, 1 mM 
MgCl2, pH 7.4) was used in binding experiments at the Y2R and Y4R. For binding 
experiments at the Y5R, buffer I was supplemented with glycine (final concentration 0.3 M) to 
reach iso-osmotic conditions as hypotonic conditions were not tolerated by HEC-1B cells 
expressing the human Y5R. Buffer II. Binding experiments at the Y1R, Y2R, Y4R and Y5R 
were performed in a buffer containing 10 mM HEPES, 150 mM NaCl, 25 mM NaHCO3, 
2.5 mM CaCl2 · 2 H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 · 7 H2O and 5 mM KCl. Binding 
buffer. The respective buffer containing 1% BSA and 0.1 g/L bacitracin was used for dilutions 
of the compounds and in binding experiments.  
 
5.2.7 Radioligand binding assay 
Radioligand binding assays were performed at 22 ± 1 °C. Cells (200 μL suspension per well) 
were seeded into 96-well plates with clear bottom (Corning Incorporated Life Sciences, 
Tewksbury, MA; cat. no. 3610). 
Y1R binding. Competition binding experiments with the radioligand [3H]propionyl-pNPY (Kd = 
6.6 nM, c = 5 nM) were performed at intact MCF-7-Y1 cells as previously described (Kuhn et 
al., 2016). In saturation binding experiments, a concentration range of 0.25 - 60 nM of the 
radioligand was covered in buffer I supplemented with 0.3 M glycine and buffer II, 
respectively. Nonspecific binding was determined in the presence of a 200-fold excess of 
BIBP3226 (N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine amide) (Rudolf et al., 
1994). Incubation period was 90 min. After incubation, the cells were processed as 
previously described (Kuhn et al., 2016). 
Y2R binding. Binding experiments were performed at CHO-hY2R-Gqi5-mtAEQ cells (Ziemek 
et al., 2006) with [3H]propionyl-pNPY as previously described (Kuhn et al., 2016). Saturation 
binding experiments were performed in a concentration range of 0.25 - 18 nM of the 
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radioligand, when using buffer I, 0.5 – 60 nM when using buffer I supplemented with 0.3 M 
glycine and 0.3 M sucrose, respectively, or 2.5 - 200 nM when using buffer II. Nonspecific 
binding was determined in the presence of a 100-fold excess of pNPY. The samples were 
processed as previously described (Kuhn et al., 2016). 
Y4R binding. All binding assays with [³H]8 and [³H]12 were performed at intact CHO-hY4R-
Gqi5-mtAEQ cells (Ziemek et al., 2007) as previously described for the CHO Y2R cells, which 
were attached to the plate (Kuhn et al., 2016). Saturation binding experiments of [3H]8 were 
performed in buffer II with following modifications: One day prior to the experiment, the cells 
(500 μL suspension per well) were seeded into PrimariaTM 24-well plates (Corning Life 
Sciences, Oneonta, NY). The cells were allowed to attach at 37 °C, 5 % CO2 in a water-
saturated atmosphere overnight. On the day of the experiment, confluency of the cells was 
approximately 90 %. The culture medium was removed by suction, the cells were washed 
with 500 μL of buffer II and covered with 200 μL of the binding buffer per well. Saturation 
binding experiments with [3H]8 were performed in a concentration range of 0.1 - 30 nM. 
Nonspecific binding was determined in the presence of a 200-fold excess of [Lys4]hPP. After 
90 min of incubation, the solution was removed by suction, and the cells were washed twice 
with buffer II (500 μL, 4 °C) followed by the addition of lysis solution (200 μL). The lysis 
solution was transferred into 6-mL scintillation vials filled with scintillator (3 mL). The vials 
were gently shaken and kept in darkness for at least 1 h prior to counting.  
Competition binding experiments were performed in the 96-well format with increasing 
concentrations of unlabeled compounds using the radioligand [3H]8 at a concentration of 
5 nM in buffer II as previously described for the CHO Y2R cells (Kuhn et al., 2016). 
Nonspecific binding was determined in the presence of a 100-fold excess of hPP. Kinetic 
experiments were performed with a radioligand concentration of 10 nM in BD PrimariaTM 24-
well plates as described for saturation binding experiments. Nonspecific binding was 
determined in the presence of 7 (1 µM). For association experiments, the incubation of the 
cells was stopped after different periods of time (2 – 150 min) by removing the radioligand-
containing medium, and cells were washed twice with ice-cold buffer (200 μL). In case of 
dissociation experiments, cells were pre-incubated with [³H]8 (10 nM) for 90 min. The 
solution was removed by suction, and the cells were covered with binding buffer (200 μL) 
containing a 100-fold excess of 7. After different periods of time (5 – 140 min) the cells were 
washed with ice-cold buffer. The solution was removed by suction, and the cells were 
washed with buffer (500 μL, 4 °C) followed by the addition of lysis solution (200 μL). The lysis 
solution was transferred into 6-mL scintillation vials filled with scintillator (3 mL). The vials 
were gently shaken and kept in darkness for at least 1 h prior to counting.  
Binding assays with the radioligand [3H]12 were performed at intact CHO-hY4R-Gqi5-mtAEQ 
cells (Ziemek et al., 2007) as previously described for the CHO Y2R cells (Kuhn et al., 2016). 
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All experiments were performed in binding buffer I (sodium-free HEPES buffer) and binding 
buffer II, respectively. Saturation binding experiments were performed in a concentration 
range of 0.1 - 18 nM (buffer I) or 0.5 – 120 nM (buffer II). For investigations of the “sodium 
effect”, buffer I was supplemented with glycine (final concentration 0.3 M) or with sodium 
chloride at different concentrations (final concentrations: 50 mM, 100 mM) in saturation 
binding experiments. Additionally, buffer I containing 50 mM NaCl was adjusted with glycine 
(final concentration 0.19 M) to obtain iso-osmotic conditions. Competition binding 
experiments were performed with increasing concentrations of unlabeled compounds using 
the radioligand [3H]12 at a concentration of 1 nM in buffer I or 5 nM in buffer II. Nonspecific 
binding was determined in the presence of a 100-fold excess of 11. The incubation period 
was 90 min. Kinetic experiments were performed with radioligand concentrations of 1 nM in 
buffer I and 5 nM in buffer II. The cells were adjusted to a density of approximately 170,000 
per mL in Ham’s F12 (Sigma Aldrich) supplemented with 10% FCS. The cells were allowed 
to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. On the day of the 
experiment, confluency of the cells was approximately 90%. The culture medium was 
removed by suction, the cells were washed with 200 μL of the respective buffer and covered 
with 80 μL of the respective binding buffer per well. Nonspecific binding was determined in 
the presence of 11. For association experiments, incubation of the cells was stopped after 
different periods of time (2 – 220 min) by removing the radioligand-containing medium, and 
cells were washed twice with ice-cold buffer (200 μL). In case of dissociation experiments, 
cells were pre-incubated with [³H]12 for 120 min. The solution was removed by suction, and 
the cells were covered with binding buffer (100 μL) containing a 100-fold excess of 11. After 
different periods of time (5 – 260 min) the cells were washed with ice-cold buffer. The 
solution was removed by suction, and the cells were washed with the respective ice-cold 
buffer (1 × 200 μL) followed by the addition of lysis solution (25 μL). The plates were shaken 
for 30 min followed by the addition of 200 μL of liquid scintillator (Optiphase Supermix). The 
plates were sealed and handled as described (Kuhn et al., 2016). 
Y5R binding. Competition binding experiments were performed at HEC-1B-hY5R cells 
(Moser, 2000) with [3H]propionyl-pNPY (buffer I: Kd = 24.5 nM; c = 4 nM; buffer II: Kd = 11.0 
nM, c = 4 nM) and [3H]12 (buffer I: Kd = 16.4 nM; c = 10 nM; buffer II: Kd = 11.4 nM, 
c = 10 nM). The cells were processed as previously described (Kuhn et al., 2016). In 
saturation binding experiments, a concentration range of 0.5 - 120 nM ([3H]propionyl-pNPY) 
and 0.25 - 80 nM ([3H]12) of the respective radioligand was covered. Nonspecific binding was 
determined in the presence of a 100-fold excess of pNPY. The plates were handled as 
described previously (Kuhn et al., 2016). In saturation binding experiments with [³H]8, 
performed in the 24-well format in buffer II, a concentration range of 0.5 - 30 nM of the 
radioligand was covered. Nonspecific binding was determined in the presence of a 200-fold 
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excess of CGP 71683A. The plates were processed as previously described for 24-well 
plates. 
 
5.2.8 Flow cytometric binding assay at the Y4R and the Y5R 
The flow cytometric Y4R binding assays on CHO-hY4-Gqi5-mtAEQ cells and Y5R saturation 
binding assays on HEC-1B-hY5R cells using 13 as fluorescent ligand were performed as 
previously described for Cy5-[Lys4]hPP on a FACSCalibur flow cytometer (Becton 
Dickinson), equipped with an argon laser (488 nm) and a red diode laser (635 nm) (settings: 
FSC: E-1, SSC: 280 V, Fl-4:700−750 V) (Ziemek et al., 2007). The cell density in the 
respective binding buffer was 106 cells/mL. The samples were incubated in 1.5 mL reaction 
vessels in the dark at rt for 90 min. The dissociation constant (Kd value) of 13 was 
determined in saturation experiments applying concentrations from 0.75 to 140 nM (buffer I 
and buffer I containing 0.3 M glycine) and 0.75 to 180 nM (buffer II), respectively. Nonspecific 
binding was determined in the presence of a 100-fold excess of hPP. The Kd value of 13 at 
the Y5R was determined in saturation experiments applying concentrations from 0.75 to 
290 nM (buffer II). Nonspecific binding was determined in the presence of an 80-fold excess 
of CGP 71683A. Data acquisition was stopped after counting of 10,000 − 15,000 gated 
events. For competition binding studies at the Y4R (c(13) = 10 nM), nonspecific binding was 
determined by addition of hPP (final concentration: 1 μM). Association kinetics was 
determined by incubation of the cells with 13 at a constant concentration (10 nM). Samples 
were taken at different time periods and measured. Nonspecific binding was measured in the 
presence of a 100-fold excess of 11. For dissociation experiments cells were pre-incubated 
with the labeled ligand (10 nM) for 60 min in the respective binding buffer. For nonspecific 
binding, pre-incubation was performed in the presence of a 100-fold excess of 7. Afterwards, 
cells were centrifuged (3.5 min, 2000 rpm) and resuspended in the respective binding buffer 
containing 7 (80-fold excess). Samples were taken at different time periods and measured. 
 
5.2.9 Luciferase assay 
The Luciferase assay was performed on HEK293T-hY4-CRE Luc cells as previously 
described (cf section 4.3.2; (Kuhn et al., 2016)). 
 
5.2.10 Arrestin recruitment assay 
The β-arrestin recruitment was quantified via a split-luciferase complementation assay as 
described for the H1 histamine receptor (Lieb et al., 2016). In brief, one day before the 
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experiment, HEK293T-ARRB1-Y4R and HEK293T-ARRB2-Y4R cells were trypsinized (0.05% 
trypsin, 0.02% EDTA in PBS) and centrifuged (400 g, 5 min). The cells were resuspended in 
DMEM without phenol red (Sigma, Steinheim, Germany) supplemented with 5% FCS, and 
90 µL of the cell suspension were seeded in white, TC-treated, flat bottom 96-well microtiter 
plates (VWR, Ismaning, Germany) at a density of approximately 100,000 cells/well. The cells 
were cultivated at 37 °C overnight in a water-saturated atmosphere containing 5% CO2. 
Shortly before the experiment, the cells were removed from the incubator and allowed to 
equilibrate to room temperature, and 10 µL of agonist solution were added per well. The 
plates were shaken at 25 °C for 60 min. At the end of the incubation period, 50 µL of medium 
were replaced by 50 µL of Bright-Glo luciferase assay reagent (Promega, Mannheim, 
Germany). The plates were vigorously shaken (800 rpm) for 5 min. Bioluminescence was 
recorded for 1 s per well using a GENios Pro microplate reader (Tecan, Salzburg, Austria). 
 
5.2.11 Confocal microscopy 
Two days prior to the experiment CHO-hY4-Gqi5-mtAEQ cells were trypsinized and seeded in 
an ibiTreat µ-slide chamber with 8 wells (Ibidi, Martinsried, Germany) in Ham’s F12 and 5% 
FCS. On the day of the experiment, confluency of the cells was 30 - 60%. The culture 
medium was removed, and the cells were washed twice with the respective buffer (buffer I, 
buffer I containing 0.3 M glycine, buffer II; 400 μL). The cells were covered with 3.5 µg/mL 
Hoechst 33342 staining solution (Invitrogen, Karlsruhe, Germany) (150 μL) as nuclear 
counterstain and incubated for 10 min protected from light. After incubation the staining 
solution was removed, the cells were washed twice (400 µL) and covered with the respective 
buffer (200 µL) containing the fluorescent ligand 13 (10 nM) were added for total binding. 
Nonspecific binding was determined in the presence of hPP (1 µM). Images were acquired 
after an incubation period of 2 – 120 min. Confocal microscopy was performed with a Leica 
SP8 microscope. An HC PL APO CS2 63x/1.40 oil immersion objective was used. Hoechst 
33342 was excited at 405 nm (laser transmission: 1%), and emission was detected in the 
range of 415 – 470 nm. The fluorescent ligand 13 was excited at 633 nm (laser transmission: 
5%), and emission was detected in the range of 645 nm – 768 nm. Accordingly, fluorescence 
crosstalk could be excluded. 
 
5.2.12 Data analysis 
All data are presented as mean ± SEM from at least two independent experiments performed 
in triplicate, in case of flow cytometric experiments in duplicate. Concentration response 
curves from the luciferase assay and displacement curves from radioligand binding 
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experiments were analyzed by four-parameter sigmoidal fits (GraphPad Prism 5.0, San 
Diego, CA). Agonist potencies are given as EC50 values, maximal responses (efficacies) are 
expressed as α value referred to the effect of 1 μM hPP (α = 1.0). Ki values were calculated 
from IC50 values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Specific 
binding data from saturation binding experiments was plotted against the ‘free’ radioligand 
concentration and analyzed according to a two-parameter hyperbolic curve fit (Binding – 
Saturation: One site – Specific binding, GraphPad Prism 5.0, San Diego, CA, USA). The 
resulting Bmax value was used to calculate the number of binding sites per cell. Specific 
binding data from association experiments were analyzed with an equation describing a two-
parameter exponential rise to a maximum (GraphPad Prism 5.0), giving the observed 
association constant kobs. Specific binding data from dissociation experiments were fitted 
according to a one-phase exponential decay (GraphPad Prism 5.0). Kinetically derived 
dissociation constants Kd(kin) were calculated from the association rate constant kon and koff (kon 
= (kobs-koff)/[L]; Kd(kin) = koff/kon). 
 
5.3 Results and discussion 
5.3.1 Synthesis of the tritiated and fluorescently labeled peptides 
For the preparation of [³H]propionyl-[Lys4]hPP ([³H]8) the precursor [Lys4]hPP (7) was treated 
with succinimidyl [3H]propionate (Scheme 5.1, Supporting Information). After purification by 
RP-HPLC, the radioligand [³H]8 was obtained in a radiochemical purity of 90% (Supporting 
Information Figure S1). After storage in EtOH/10 mM HCl 2:98 (v/v) at 4 °C an increasing 
amount of decomposition products became obvious in the radiochromatogram, and after two 
years, only approximately 5% of [³H]8 were left (Supporting Information Figure S2). 
[3H]propionyl-[Lys4,Nle17,30]hPP ([³H]12) was prepared in the same way as [3H]8 from 
[Lys4,Nle17,30]hPP (11) (cf. Supporting Information) and succinimidyl [3H]propionate affording 
the radioligand with a specific activity of 1.532 TBq/mmol in a radiochemical purity of 92%. 
Unlike [3H]8, [3H]12 showed excellent chemical stability when stored in 10% ethanol at 4 °C 
(Figure 5.2A, B). No decomposition was observed after an incubation period of 48 h, when 
the ‘cold’ analogs, 12 (Figure 5.3A) and 8 (cf. Supporting Information, Figure S5), both 
prepared by analogy with the radioligands, and [Lys4,Met(O)17,30]hPP (9) were investigated 
for stability in a HEPES buffer (buffer I, pH 7.4). In case of 9 a small peak was observed with 
the same retention time as that of [Lys4,Met(O2)17,30]hPP (10) (tR = 7.9 min; <1%) after 48 h 
(cf. Supporting Information, Figures S6 and S7).  
The fluorescent ligand S0223[Lys4,Nle17,30]hPP (13) was prepared by treating an 1.3-fold 
excess of amine precursor 11 with the succinimidyl ester of the cyanine dye S0223 (S2197) 
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(Scheme 5.1). The fluorescent ligand 13 was isolated by RP-HPLC and obtained in a 
chemical yield of 62% and high purity (Figure 5.2C). The compound proved to be sufficiently 
stable during incubation in buffer I for up to 48 h (Figure 5.3B).  
 
Figure 5.2. Purity, identity and long-term stability of the radiolabeled peptide [3H]12 and the 
fluorescent ligand 13 determined by HPLC. (A) HPLC analysis of [3H]12 (ca. 0.15 µM) spiked with 
‘cold’ 12 (25 µM). Radiochemical purity: 92%. (B) HPLC analysis of [3H]12 (ca. 0.10 µM) spiked with 
‘cold’ 12 (25 µM), analyzed after 7 months of storage at 4 °C in EtOH/H2O (10:90); injection volume: 
100 µL. Radiochemical purity: 88%. The minor differences in tR result from serial detection of the UV 
and radiometric signals. (C) HPLC analysis of 13 1 day after synthesis at 220 nm, chemical purity: 
96%. (D) HPLC analysis of 13 1 day after synthesis at 630 nm. 
 
Figure 5.3. HPLC analysis of ‘cold’ 12 (A) and the fluorescent peptide 13 (B) after incubation in 
buffer I (HEPES buffer, sodium-free, pH 7.4) for up to 48 h. Compound 12 showed no decomposition, 
whereas in case of 13 two small additional peaks (tR = 6.6 min, tR = 8.0 min) corresponding to <3.5% 
of the peak areas were detected after 48 h of incubation. For 13 a different gradient was applied. 
Peaks between 0 and 6 min correspond to buffer components. 
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5.3.2 Functional studies at the hY4R 
The peptides were investigated for Y4R agonism in a luciferase gene reporter assay on 
HEK293T cells expressing the hY4R as well as in β-arrestin1 and β-arrestin2 recruitment 
assays (split luciferase complementation assays) by using HEK293T-ARRB1-Y4R and 
HEK293T-ARRB2-Y4R cells (data T.Littmann, personal communication). 
 
Table 5.1. NPY hY4R agonist potencies (EC50) and intrinsic activities (α) of selected peptides 
and reference compound hPP. 
Compound 
Luciferase assay 
EC50 [nM]a 
 
 
α 
 Arrestin assay 
 EC50 [nM]b 
 
α 
β-arrestin isoform 
 
 
 
s 
 
 su suc 
 
 
hPP 0.6 ± 0.1 1.0 
 
 
  4.4 ± 0.02 
 
1.0 1 
     3.1 ± 0.01 1.0 2 
4         5.5 ± 0.8 1.01  413 ± 2 0.53 1 
    236 ± 2 0.63 2 
7 1.5 ± 0.2 0.99   7.3 ± 0.03 0.75 1 
     5.0 ± 0.03 0.88 2 
8 3.5 ± 0.4 0.97    15 ± 0.08 0.81 1 
      10 ± 0.04 0.89 2 
9 4.2 ± 0.3 1.02    42 ± 0.18 0.72 1 
      27 ± 0.12 0.79 2 
10 1.9 ± 0.4 0.99    10 ± 0.05 0.71 1 
     6.4 ± 0.02 0.80 2 
11 0.9 ± 0.1 1.00    15 ± 0.05 0.74 1 
      10 ± 0.03 0.86 2 
12 1.0 ± 0.1 0.99    14 ± 0.09 0.79 1 
     9.2 ± 0.04 0.83 2 
13         3.1 ± 0.9 1.00    19 ± 0.12 0.84 1 
      13 ± 0.10 0.89 2 
aCRE-luciferase reporter gene assay on HEK293T cells stably co-expressing the hY4R and the CRE-
controlled luciferase gene reporter. Y4R agonist potency was determined by the inhibition of forskolin 
(2 μM) stimulated luciferase activity. bArrestin recruitment assay on HEK293T-ARRB1-Y4R and 
HEK293T-ARRB2-Y4R cells. The maximal response (intrinsic activity, α) is referred to the effect of 
hPP set to α = 1.0. Data represent mean values ± SEM from at least two independent experiments 
performed in triplicate. 
 
 
All investigated peptides were full agonists in the gene reporter assay. The potencies were 
essentially comparable, regardless of the oxidation state of the sulfur atoms, the replacement 
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of methionine by norleucine and the derivatization of the lysine in both, 7 and 11. As 
differences between agonist potencies and intrinsic activities may be masked due to signal 
amplification in assays with distal readouts such as gene reporter assays, the peptides were 
also tested in a -arrestin recruitment assay, a system with a rather proximal readout. In this 
assay, the rank order of potencies was similar compared to that determined in the luciferase 
assay, but the EC50 values were higher. A slight preference for the isoform 2 of -arrestin 
became obvious. Contrary to the gene reporter assay, all peptides showed partial agonism 
with intrinsic activities between 0.7 and 0.9. In literature, 4 was reported both, as a partial 
(Berglund et al., 2003b; Ziemek et al., 2007) and a full Y4R agonist (Berglund et al., 2003a; 
Parker et al., 1998). Compared to the luciferase assay, 4 turned out to be 40-75 times less 
potent and a partial Y4R agonist in the -arrestin assay, achieving 50-60% of the maximal 
response, that is, the difference between data from both assays was most pronounced in 
case of compound 4. Regardless of being aware of the different extent of signal amplification 
in luciferase gene reporter and split luciferase complementation assay, this discrepancy may 
reflect G protein bias. 
 
5.3.3 Y4R binding of the radiolabeled and fluorescence labeled compounds 8, 
12 and 13  
More detailed binding studies were performed on intact CHO-hY4-Gqi5-mtAEQ cells in a 
hypotonic sodium-free buffer (buffer I, HEPES) (compounds [³H]12 and 13) and an isotonic 
buffer (buffer II, HEPES, 150 mM sodium) (compounds 8, [³H]12 and 13). The radioactive 
form of propionyl-[Lys4]hPP was characterized by saturation and kinetic binding experiments 
(cf. Supporting Information Figures S10 and S11) within 4 months after purification. 
Saturation binding studies with [3H]propionyl-[Lys4]hPP at live CHO cells expressing the 
hY4R revealed a Kd value of 6.0 nM. The number of specific binding sites per cell amounted 
to approximately 252,000 and was in the same range as previously reported (Kuhn et al., 
2016). At concentrations around the Kd value, nonspecific binding amounted to 5 % of the 
total binding. Association to the receptor was complete after 100 min (kobs = 0.0293 min-1). 
Dissociation from the receptor was monophasic with a koff of 0.0118 min-1. The kinetically 
derived Kd (koff/kon = 25.5 nM) was in the same order of magnitude as the Kd from saturation 
binding experiments. To investigate the impact of sodium ions on the Kd value of [3H]12, 
buffer I was supplemented with sodium chloride at different concentrations. An increasing 
sodium concentration in buffer I led to higher Kd values (Figure 5.4). To investigate whether 
this effect was sodium dependent or related to the hypotonic character of buffer I, the 
osmolarity was adjusted by addition of glycine (concentration: 0.3 M in the absence of NaCl 
and 0.19 M in the presence of 50 mM NaCl; Figure 5.4; cf. Supporting Information Table S2, 
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Figure S12). Saturation binding studies with [3H]12 at live CHO cells expressing the hY4R 
revealed a 20-fold higher Kd value of 20.9 nM (buffer II) in comparison to saturation binding 
performed in buffer I (Kd = 1.1 nM) (Figure 5.4, Table 5.2). At concentrations around the Kd 
value, nonspecific binding amounted to 2% of the total binding in buffer I and 5% in buffer II. 
Association to the receptor was complete after 130 min (buffer I: kobs = 0.0169 min-1; Figure 
5.5A) and 70 min (buffer II: kobs = 0.0387 min-1, Figure 5.5C), respectively. Dissociation from 
the receptor was monophasic (Figure 5.5B and Figure 5.5D) with a koff of 0.0110 min-1 
(buffer I) and 0.0292 min-1 (buffer II), respectively. After 250 minutes, the residual specific 
binding of the tritiated compound amounted to approximately 13% (buffer I) and 31% 
(buffer II), respectively, suggesting in part (pseudo)irreversible binding. The kinetically 
derived Kd (buffer I: koff/kon = 1.9 nM; buffer II: 15.4 nM) was in excellent agreement with the 
Kd from saturation binding experiments (buffer I: 1.1 nM; buffer II: 20.9 nM). 
 
 
Figure 5.4. Y4R saturation binding of the radioligand [³H]12 depending on NaCl content and 
hypotonicity. Data determined at CHO-hY4-Gqi5-mtAEQ cells at 22 °C in buffer I, buffer I 
supplemented with 0.3 M glycine or with sodium chloride at different concentrations (0 mM, 50 mM, 
100 mM), buffer I supplemented with 50 mM sodium chloride and 0.19 M glycine for iso-osmotic 
conditions, and buffer II (150 mM Na+). (A, B) Representative saturation binding experiments with 
[³H]12. (C) Determined correlation between Na+ concentration and Kd value; r² = 0.98. Data from at 
least two independent experiments performed in triplicate. 
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Figure 5.5. Y4R binding characteristics of the radioligand [³H]12. Data determined at CHO-hY4-Gqi5-
mtAEQ cells at 22 °C in buffer I (HEPES, sodium-free) (A, B) and buffer II (HEPES, 150 mM Na+) 
(C, D). (A, C) Y4R association kinetics of [³H]12 (buffer I: c = 1 nM; buffer II: c = 5 nM). Inset: 
Linearization ln[Beq/(Beq-Bt)] versus time. (B, D) Y4R dissociation kinetics of [³H]12 (buffer I: c = 1 nM; 
buffer II: c = 5 nM, pre-incubation time: 2 h) determined in the presence of a 100-fold excess of 11. 
Fitting of the data according to a monophasic exponential decay. Inset: Linearization ln[B/B0] versus 
time. Data represent mean values ± SEM from two independent experiments performed in triplicate. 
 
Flow cytometric saturation binding studies with the fluorescent ligand 13 at hY4R-expressing 
CHO cells revealed comparable Kd values in buffer I (Kd = 9.2 nM), buffer I containing 0.3 M 
glycine (Kd = 9.4 nM) and buffer II (Kd = 16.5 nM) (Figure 5.6A and Figure 5.6D; Supporting 
Information, Figure S13). At concentrations around the Kd value, nonspecific binding 
amounted to 3% of the total binding in buffer I and 5% in buffer II. Association to the receptor 
was complete after 25 min (buffer I: kobs = 0.08312 min-1, Figure 5.6B; buffer II: 0.1209 min-1, 
Figure 5.6E). Dissociation from the receptor was monophasic (Figure 5.6C) with a koff of 
0.1664 min- 1 in buffer I. After 15 minutes, the residual specific binding of the compound 
amounted to approximately 30%. In the isotonic buffers, buffer I containing glycine and 
buffer II, the fluorescent ligand showed low nonspecific binding (8% of total binding). 
However, after incubation of the cells for 60 min, 13 was not displaceable by an excess of 7 
(Figure 5.6F, Supporting Information Figure S13). Therefore, the cellular localization of the 
fluorescent ligand was studied by confocal microscopy. 
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Figure 5.6. Y4R binding characteristics of the fluorescent ligand 13. Data determined by flow 
cytometry at CHO-hY4-Gqi5-mtAEQ cells at 22 °C in buffer I (HEPES, sodium-free) (A, B, C) and 
buffer II (HEPES, 150 mM sodium) (D, E, F). (A, D) Representative saturation binding experiments 
with 13. (B, E) Representative Y4R association kinetics of 13 (c = 10 nM). Inset: Linearization 
ln[Beq/(Beq-Bt)] versus time. (C, F) Representative Y4R dissociation kinetics of 13 (c = 10 nM; pre-
incubation time: 60 min) determined in the presence of an 80-fold excess of 7. Fitting of the data 
according to a monophasic exponential decay. Inset: linearization ln[B/B0] versus time. Buffer II: 
dissociation of 13 was not observed. 
 
Table 5.2. Binding data of [³H]8, [³H]12 and 13 in buffers I and II. 
 Saturation binding Binding kinetics 
Compound Kd [nM]a kobs [min-1]b koff [min-1]c Kd(kin) [nM]d 
[³H]8   6.0 ± 1.3f 0.0239f 0.0172f 25.5f 
[³H]12   1.1 ± 0.1e 0.0169e 0.0110e 1.86e 
 20.9 ± 2.0f 0.0387f 0.0292f 15.37f 
13   9.2 ± 2.5e 0.0831e 0.1664e  
 
16.5 ± 2.3f 0.1209f - - 
[a] Equilibrium dissociation constant determined on CHO-hY4-Gqi5-mtAEQ cells; mean ± SEM from at 
least two independent experiments performed with [³H]8, [³H]12 (in triplicate) and 13 (in duplicate), 
respectively. [b] Apparent association constant, mean from two independent experiments performed 
with [³H]8, [³H]12 (in triplicate) and 13 (in duplicate) respectively. [c] Dissociation constant, mean from 
two independent experiments performed with [³H]8, [³H]12 (in triplicate) and 13 (in duplicate), 
respectively. Monophasic exponential fit. [c] Kinetically derived dissociation constant Kd(kin), calculated 
from the association rate constant kon and koff ([³H]8: kon = (kobs-koff)/[L] = 0.00068 nM-1*min-1 ; [³H]12: 
kon=(kobs-koff)/[L]= 0.0059 nM-1 · min-1(buffer I); kon=0.0019 nM-1 · min-1 (buffer II); Kd(kin) = koff/kon). 
[e] Data determined in buffer I. [f] Data determined in buffer II. 
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5.3.4 Confocal microscopy of CHO hY4R cells incubated with the fluorescent 
ligand 13 
In accordance with the results from flow cytometric binding experiments, the nonspecific 
binding determined in the presence of a 100-fold excess of non-fluorescent hPP was low, 
irrespective of the composition of the buffer (Figure 5.7). In the absence of the competitor 
hPP, the fluorescent ligand 13 showed no time-dependent intracellular accumulation when 
the cells were incubated in hypotonic buffer I. It should be noted that the cells swell 
considerably under these conditions (cf. Supporting Information, Fig. S14). By contrast, the 
ligand was significantly enriched intracellularly with time in isotonic buffers, that is, buffer I 
containing glycine or buffer II, respectively. Low cellular accumulation in the presence of hPP 
indicates receptor-mediated internalization of the fluorescent ligand. This explains why 
compound 13 remained cell-associated when flow cytometric dissociation experiments were 
performed after pre-incubation of the cells with the fluorescent ligand for 60 min in isotonic 
buffers (Figure 5.6F, Supporting Information Figure S13B). Regardless of that, competition 
binding experiments with 13 can be performed as shown below. Obviously, the extent of 
internalization is positively correlated with the number of Y4Rs occupied by the fluorescent 
ligand. 
 
Figure 5.7. Time–dependent binding of the fluorescent ligand 13 at CHO hY4R cells in different buffers 
(buffer I (hypotonic); buffer I containing 0.3 M glycine and buffer II (isotonic)). Cells were incubated 
with the fluorescent ligand (10 nM) at room temperature. Nonspecific binding was determined in the 
presence of 1 µM hPP. All images were acquired with a Leica SP 8 microscope. Settings: 63x/1.40 
objective, Hoechst 33342 as nuclear counterstain (red), 13 (green), 75 µm pinhole; scale bar: 20 µm. 
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The different sensitivity of the binding of the radioligand and the fluorescent ligand with 
respect to the composition of the buffer was surprising as both ligands are derivatives of the 
same peptide. In principle, mechanical stretch, here the swelling of the cells (cf. Supporting 
Information, Figure S14), can induce a switch of the GPCR conformation from the inactive to 
the active state (Zou et al., 2004). However, the sodium concentration rather than the 
osmolarity effected the binding affinity of the radioligand [³H]12. This is in agreement, e. g., 
with studies on the influence of alkali cations on Y4R binding of [125I]hPP (Parker et al., 2004) 
and on vasopressin V1b receptor binding of [3H]AVP (Koshimizu et al., 2016). By contrast, 
the osmolarity of the buffer was crucial in case of the fluorescent ligand 13, as isotonic 
conditions regardless of the nature of the osmotically active ingredients, especially, Na+ and 
glycine, decreased the affinity and increased the receptor-mediated internalization of the 
fluorescent ligand. This can not be explained yet, but there is clear evidence that binding 
affinity and the extent of internalization strongly depend on the type of the label attached to 
the hY4R agonist. Depending on hypotonic or isotonic conditions, distinct distributions of the 
cell populations became obvious in the scattergram (cf. Supporting Information Figure S15).  
 
5.3.5 Y4R competition binding 
The radioligand [³H]8 was used for the determination of binding data of hPP, 7 and 8 on the 
Y4R in buffer II (Supporting Information Figure S16). The Ki values of hPP (Ki = 0.86 ± 
0.02 nM), 7 (Ki = 4.2 ± 0.1 nM), and 8 (Ki = 9.1 ± 0.9 nM) were in good agreement with data 
determined with the radioligand [³H]12 in buffer II (cf. Table 1.3). In case of the ‘cold’ analog 
of the radioligand, propionyl-[Lys4]hPP, the Ki value was in good agreement with the Kd value 
(9.1 nM vs. 6.0 nM). 
The binding data of the peptides 7 - 13 and the reference compounds hPP, 4 and 6, were 
determined at the Y4R, using the radioligand [³H]12 and the fluorescent ligand 13 in buffer I 
and buffer II (cf. Figure 5.8, Table 5.3). In radioligand and fluorescent binding studies Ki 
values of hPP and UR-MK188 (6) were in good agreement with published data (Ki(hPP): 
0.50 nM (Keller et al., 2016), 0.53 nM (Berlicki et al., 2013); Ki(6): 130 nM (Keller et al., 
2013)). In case of the ‘cold’ analog of the radioligand 12 (buffer I: 1.5 nM; buffer II: 14.3 nM) 
and the fluorescent peptide 13 (buffer I: 4.2 nM; buffer II: 9.1 nM), the Ki values were in good 
agreement with the Kd values (cf. Table 5.2). Generally, the Ki values of the peptides at the 
Y4R determined in buffer I were in excellent agreement with the EC50 values determined in 
the functional assay (Table 5.1). Interestingly, in buffer II higher Ki values were determined 
for all peptides. As previously reported, the affinities of hPP(Parker et al., 2002) and of the 
antagonist 6 (Kuhn et al., 2016) remained unaffected by an exchange of the binding buffer. 
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A clear difference in affinity became obvious in case of 9 and 10 when using buffer I or 
buffer II (Table 5.3). The impact of the composition of the buffer was most pronounced for 4 
(buffer I: Ki = 2.2 nM; buffer II: Ki = 242 nM).  
 
 
Figure 5.8. Displacement curves from competition binding experiments performed with [3H]12 and 
the fluorescent ligand 13. Data determined at CHO-hY4R-Gqi5-mtAEQ cells in buffer I (solid lines) and 
buffer II (dashed lines). (A) Displacement of [3H]12 (buffer I: Kd = 1.1 nM, c = 1.0 nM; buffer II: 
Kd = 20.9 nM, c = 5.0 nM). (B) Displacement of 13 (buffer I: Kd = 10.8 nM, c = 10 nM; buffer II: 
Kd = 16.5 nM, c = 10 nM). Data represent mean values ± SEM of at least three independent 
experiments performed in triplicate (A) or duplicate (B). 
 
Table 5.3.Y4R binding data determined with 13 and [3H]12 in buffer I and buffer II. 
 
               13 Ki [nM]a         [³H]12 Ki [nM]b 
Ratio of Ki   
(buffer II: buffer I) 
Compd. buffer I buffer II buffer I buffer II 13 [³H]12 
hPP 0.45 ± 0.04 1.4 ± 0.20  0.6 ± 0.1   0.8 ± 0.1 3 1 
4 1.91 ± 0.42  518 ± 127  2.2 ± 0.1  242 ± 58 271 111 
6  187 ± 32  216 ± 28 296 ± 5.2  239 ± 36 1 1 
7 1.93 ± 0.2 21.5 ± 2.3  1.3 ± 0.2   7.6 ± 1.4 11 6 
8 - -  2.2 ± 0.2   9.1 ± 0.6 - 4 
9 15.9 ± 3.1  232 ± 24  1.8 ± 0.3    92 ± 5 15 52 
10   4.1 ± 0.5 33.3 ± 9.6  0.7 ± 0.1 19.0 ± 2.3 8 27 
11   2.3 ± 0.7 22.7 ± 3.5  0.8 ± 0.0   7.9 ± 1.0 10 10 
12   7.1 ± 0.9 33.9 ± 4.5  1.5 ± 0.2 14.3 ± 3.3 5 9 
13 - -  4.2 ± 0.2   9.1 ± 0.9 - 2 
[a] Flow cytometric binding assay with 13 (c = 10 nM). [b] Radioligand competition binding assay with 
[3H]12 (buffer I: c = 1 nM; buffer II: c = 5 nM). Data represent mean values ± SEM of at least three 
independent experiments performed in triplicate (a) or duplicate (b) on CHO cells stably expressing 
the Y4R. 
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5.3.6 NPY receptor subtype selectivity  
The Ki values of the peptides were also investigated in competition binding experiments on 
live cells expressing human Y1, Y2 and Y5 receptors to determine the NPY receptor subtype 
selectivity using [3H]propionyl-pNPY as radioligand (cf. Supporting Information). The 
nonspecific binding of the latter at the respective NPY receptor expressing cells was low.  
The fluorescent ligand 13 and the ’cold’ analog of the new Y4R radioligand exhibited lower 
Y1R and Y2R affinities (>3000 nM) than the precursor 11 (three-digit nM range) (Table 5.4). 
However, all investigated peptides turned out to be high-affinity Y5R ligands with Ki values in 
the range of 10-40 nM. Interestingly, oxidation of the two thioether groups in 7 resulted in 
lower affinity at the Y5R (167 nM), whereas oxidation of methionine (cf. compounds 9, 10) 
had no impact on the Y4R affinity. Ki values of 7 and the oxidized analogs determined in 
radioligand binding experiments were in the same range. 
 
Table 5.4. NPY receptor binding data. 
[a] Radioligand competition binding assay with [3H]propionyl-pNPY (Kd = 7 nM, c = 5 nM) using MCF-
7-hY1 cells in buffer II (Keller et al., 2011a). [b] Radioligand competition binding assay with 
[3H]propionyl-pNPY (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-mtAEQ cells in buffer I (Ziemek et al., 
2006). [c] Radioligand competition binding assay with [³H]12 (Kd = 1.1 nM, c = 1 nM) using CHO-
hY4RGqi5-mtAEQ cells in buffer I. [d] Flow cytometric binding assay with 13 (Kd = 10.8 nM, c = 10 nM) 
using CHO-hY4RGqi5-mtAEQ cells in buffer I. [e] Radioligand competition binding assay with 
[3H]propionyl-pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1B-hY5R cells in buffer II (Moser, 2000). 
 
5.3.7 Effect of Na+ and osmolarity on the binding of [3H]propionyl-pNPY to the 
Y1, Y2 and Y5R and binding of [³H]8, [³H]12 and 13 to the Y5R 
Due to the observed impact of Na+ on Y4R binding, saturation binding experiments were also 
performed at the Y1R, Y2R and Y5R (Tables 5.5 and 5.6; cf. Supporting Information Figures 
S17-S19, S21) using [3H]propionyl-pNPY as radioligand. The Kd values determined at MCF-7 
 Y1R Y2R Y4R Ki [nM] Y5R 
Compd. Ki [nM]a Ki [nM]b [³H]12c 13d Ki [nM]e 
hPP >3000 >5000 0.6 ± 0.1 0.45 ± 0.04 19.8 ± 1.5 
7 249 ± 29 >6000 1.3 ± 0.2 1.93 ± 0.2   9.1 ± 1.4 
8 >1000 >1000 2.2 ± 0.2 - 18.6 ± 1.5 
9 603 ± 86 >10,000 1.8 ± 0.3 15.9 ± 3.1  167 ± 7 
10 807 ± 17 >8000 0.7 ± 0.1   4.1 ± 0.5 25.2 ± 2.8 
11 280 ± 11 962 ± 77 0.8 ± 0.0   2.3 ± 0.7 12.7 ± 0.1 
12 >4500 >7000 1.5 ± 0.2   7.1 ± 0.9 26.7 ± 5.0 
13 >5000 >3600 4.2 ± 0.2 - 39.7 ± 10 
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cells expressing the Y1R were in the same range (Kd = 5.3 nM and 6.6 nM, respectively) in 
both, buffer I supplemented with glycine (c = 0.3 M) and buffer II. At CHO cells stably 
expressing the Y2R, a Kd value (1.4 nM) could only be determined in buffer I, whereas in 
buffer II, buffer I supplemented with 0.3 M glycine or 0.3 M sucrose (cf. Supp. Information 
Table S2), saturation was not achieved at concentrations of [3H]propionyl-pNPY up to 60 and 
200 nM, respectively. The Bmax values (sites/cell) at the MCF-7-hY1 and CHO hY2 cells were 
comparable to those reported previously (Keller et al., 2011a; Pluym et al., 2013). Due to the 
high Y5R affinity of the ’cold’ analog 12, saturation binding experiments were also performed 
at HEC-1B-hY5 cells (Moser, 2000) using [³H]12 as radioligand (Table 5.6; Supporting 
Information Figure S21). An effect of Na+ on Y5R binding was detected neither for 
[3H]propionyl-pNPY nor for [3H]12 (Kd values: [3H]propionyl-pNPY: 24.5 nM (buffer I 
containing 0.3 M glycine) and 11.0 nM (buffer II); [3H]12: 11.3 nM (buffer I containing 0.3 M 
glycine) and 16.4 nM (buffer II)), although the nonspecific binding was higher in the glycine 
containing buffer. Saturation binding experiments of [³H]8 (Kd = 6.9 ± 0.9 nM) and 13 (Kd = 
26.5 ± 4.8 nM) afforded Kd values (Supporting Information Figures S20, S22) comparable to 
Ki values (cf. Table 5.4). In addition, displacement of the radioligands [3H]propionyl-pNPY 
and [3H]12 by selected compounds in both buffers revealed no impact of Na+ on ligand 
affinity. The determined Ki values of the antagonist CGP 71683A (naphthalene-1-sulfonic 
acid {trans-4-[(4-aminoquinazolin-2-ylamino)methyl]cyclohexyl-methyl}amide) (Criscione et 
al., 1998) and selected peptides were consistent regardless of the used radioligand 
(Table 5.7). 
 
Table 5.5. Kd values of [3H]propionyl-pNPY at the Y1 and Y2 receptors. 
 hY1R  hY2R  
 
Kd [nM]a  sites/cellb  Kd [nM]c  sites/cellb 
buffer Id 5.3 ± 1.9 89600 1.4 ± 0.1 236,900e 
buffer I containing 0.3 M glycine n.d.f n.d.f -g -g 
buffer I containing 0.3 M sucrose n.d.f n.d.f -g -g 
buffer II 6.6 ± 0.3 47900h -g -g 
[a] Equilibrium dissociation constant determined on MCF-7-hY1 cells; mean ± SEM from at least two 
independent experiments performed in triplicate. [b] Estimated Bmax (sites/cell) calculated from the 
determined Bmax in saturation binding experiments and the specific radioactivity of [3H]propionyl-pNPY. 
[c] Equilibrium dissociation constant determined on CHO-hY2 cells; mean ± SEM from at least two 
independent experiments performed in triplicate. [d] Buffer I containing 0.3 M glycine for experiments 
on MCF-7-hY1 cells. [e] Reported: 175,000 sites/cell (Pluym et al., 2013). [f] Not determined; saturation 
binding assay was not performed at the Y1R using the respective buffers. [g] Could not be determined; 
no saturation achieved. [h] Reported: 100,000-150,000 sites/cell (Keller et al., 2011a). 
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Table 5.7. Y5R binding data determined by competition of the radioligands [3H]propionyl-
pNPY ([³H]prop.-2) and [³H]12 in buffer I containing glycine and buffer II. 
   Ki [nM] in buffer I  Ki [nM] in buffer II 
 Ratio of Ki values,  
 buffer II : buffer I 
Compd. [³H]12a [³H]prop.-2b  [³H]12a [³H]prop.-2b  [³H]12 [³H]prop.-2 
CGP71683A    1.6 ± 0.2   3.8 ± 0.4    1.9 ± 0.4   1.4 ± 0.3  1.2 0.4 
pNPY 15.3 ± 1.1 10.7 ± 1.2  11.0 ± 1.5   6.7 ± 1.1  0.7 0.6 
7   5.2 ± 1.0   5.8 ± 0.2    7.2 ± 0.8   9.1 ± 1.4  1.4 1.6 
11   8.4 ± 1.2 11.1 ± 3.1  12.0 ± 1.2 14.1 ± 1.4   1.4 1.3 
[a] Radioligand competition binding assay with [³H]12 (buffer I containing 0.3 M glycine: Kd = 16.4 nM, 
c = 10 nM; buffer II: Kd = 11.4 nM, c = 10 nM). [b] Radioligand competition binding assay with 
[3H]propionyl-pNPY (buffer I containing 0.3 M glycine: Kd = 24.5 nM, c = 4 nM; buffer II: Kd = 11.0 nM, 
c = 4 nM); mean ± SEM from three independent experiments (performed in triplicate) using HEC-1B-
hY5R cells. 
 
 
5.4 Conclusions 
Replacement of the methionine residues in 7 by norleucine to prevent oxidation of sulfur in 
the reference compound gave the chemically more stable peptide 11, which was converted 
to radiolabeled and fluorescent molecular tools for the Y4 receptor, e. g. for the determination 
of competition binding data of Y4R ligands. Surprisingly, equilibrium binding and kinetics of 
the radioligand [3H]12 and the fluorescent ligand 13 were effected by the buffer composition 
in a different way: [3H]12 binding was dependent on the sodium concentration, whereas 
binding and receptor-mediated internalization of 13 were strongly effected by the osmolarity 
of the buffer. Fluorescent ligands are often considered superior to radioligands as molecular 
Table 5.6. Kd values of [³H]12 and [3H]propionyl-pNPY at the Y5 receptor in different      
buffers. 
 [³H]12  [3H]propionyl-pNPY 
 
Kd [nM]a  sites/cellb  Kd [nM]a sites/cellb 
buffer I + glycine 16.4 ± 2.3 941,000   24.5 ± 4.9 888,000 
buffer II 11.4 ± 0.2 1,056,000  11.0 ± 2.1 861,000c 
[a] Equilibrium dissociation constant determined on HEC-1B-hY5 cells in buffer I containing 0.3 M 
glycine and buffer II, respectively; mean ± SEM from at least two independent experiments performed 
in triplicate. [b] Estimated Bmax (sites/cell) calculated from the determined Bmax in saturation binding 
experiments and the specific radioactivity of [³H]12 and [3H]propionyl-pNPY, respectively. [c] Reported: 
1,000,000 sites/cell (Moser, 2000). 
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tools. However, the present study demonstrates that, despite an identical peptide scaffold, 
fundamental differences between both types of probes may exist and should be carefully 
taken into account in the interpretation of experimental results. 
 
5.5 Supporting Information 
5.5.1 Synthesis of the ligands [3H]propionyl-pNPY, 8 and [3H]8 
[3H]propionyl-pNPY. A solution of succinimidyl [3H]propionate (500 µL = 2.5 mCi; 32 nmol; 
specific activity: 80 Ci/mmol (2.96 TBq/mmol), purchased from American Radiolabeled 
Chemicals, St. Louis, MO via Hartman Analytics, Braunschweig, Germany) in hexane/EtOAc 
(9:1) was transferred from the delivered ampoule into a 1.5 mL reaction vessel with screw 
cap, and the solvent was removed in a vacuum concentrator (30 °C, 30 min). A solution of 
pNPY (0.5 mg, 109 nmol, in (v/v) 12.5% water, 84.75% DMF, 2.75% DIPEA) (80 µL) was 
added, and the vessel was vigorously shaken at rt for 2 h. The mixture was acidified by 
addition of 2% aqueous TFA (70 μL) followed by addition of MeCN/H2O (10:90) (180 μL). 
[3H]propionyl-pNPY was purified using a HPLC system from Waters. A Luna C18(2) column 
(3 μm, 150 × 4.6 mm, Phenomenex, Aschaffenburg, Germany) was used as stationary phase 
at a flow rate of 0.8 mL/min. Acetonitrile supplemented with 0.04% TFA (A) and 0.05% aq 
TFA (B) were used as mobile phase. The following linear gradient was applied: A/B: 0–
22 min: 10:90 – 36:64, 22–27 min: 36:64, 27–28 min: 36:64–95:5, 28–35 min: 95:5. For the 
purification of the radiolabeled peptide three HPLC runs were performed. The radioligand 
was collected in 2-mL reaction vessels with screw caps, and the volumes of the combined 
eluates were reduced by evaporation to approximately 900 μL. Ethanol (100 µL) was added 
to obtain a solution of the radioligand in 10% ethanol for storage. By four-point calibration 
with propionyl-pNPY (0.1, 0.2, 0.5 and 0.8 μM; injection volume: 100 μL, UV-detection: 
220 nm) a concentration of the radioligand of 13.65 μM was determined. For this purpose, 
two samples were prepared by diluting 2 µL of the radioligand solution with 128 μL 
MeCN/0.05% aq TFA (10:90). Volumes of 100 µL of each sample were injected. The 
following linear gradient was applied: A/B: 0–20 min: 15:85 – 50:50, 20–22 min: 50:50 – 95:5, 
22–28 min: 95:5. To measure the radioactivity, from each of the two samples 3 µL were 
counted in 3 mL of liquid scintillator (Rotiszint eco plus, Carl Roth, Karlsruhe, Germany) with 
a Beckmann LS 6500 liquid scintillation counter (Beckman Coulter, Krefeld, Germany) in 
pentuplicate. To determine the radiochemical purity and to prove the identity of the 
radioligand, a solution of the radiolabeled peptide (100 μL, final concentration: 0.25 μM), 
spiked with ‘cold’ propionyl-pNPY (final concentration: 9.1 µM) was analyzed by HPLC with 
combined UV/radiochemical detection. The radiochemical purity was > 99%. Calculated 
specific activity: 46.32 Ci/mmol (1.714 TBq/mmol). Chemical yield: 
hexa(hydrotrifluoroacetate) of [3H]propionyl-pNPY: 58.9 μg, 13.65 nmol, 42.7%. 
Radiochemical yield: 0.627 mCi (23.21 MBq), 25.1%. The stock solution of [3H]propionyl-
pNPY (c = 13.65 μM) was stored at 4 °C.  
 
Propionyl-[Lys4]hPP (8). Compound 7 (3.92 mg, 0.94 μmol) was dissolved in Millipore water 
(1500 μL), 0.1 M borate buffer (38.1 mg/mL di-sodium tetraborate decahydrate; pH 9.5; 930 
µL) and a solution of succinimidyl propionate in DCM (0.26 mg/mL) were added (300 µL). To 
prevent two-fold acylation, the reaction was monitored by HPLC. The product was purified by 
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preparative HPLC (column: Kinetex-XB C18, 5 μm, 250 mm × 21 mm, Phenomenex, 
Aschaffenburg, Germany; gradient: MeCN/10% MeCN, 0.1% aq TFA: 0–30 min: 15:85 – 
60:40, 30–38 min: 95:5; tR = 19.4 min). Lyophilisation of the eluate afforded propionyl-
[Lys4]hPP as a white fluffy solid (0.72 mg, 0.17 μmol). HRMS (m/z): [M+5H]5+ calcd. for 
C189H296N54O53S2, 847.8386; found, 847.8397. RP-HPLC (220 nm): 98% (column: Synergi 
Hydro-RP C18, 4 μm, 250 × 4.6 mm, Phenomenex; gradient: MeCN 0.04% TFA/0.05% TFA: 
0–30 min: A/B 30:70–42:58, 30–31 min: 42:58–95:5, 31–40 min: 95:5. tR = 16.2 min, k = 3.9) 
C189H296N54O53S2 · C10H5F15O10 (4239.19 + 570.10). 
 
[3H]propionyl-[Lys4]hPP ([3H]8). A solution of succinimidyl [3H]propionate 
(340 µL = 1.7 mCi; 21.2 nmol; specific activity: 80 Ci/mmol (2.96 TBq/mmol) in 
hexane/EtOAc (9:1) was transferred from the delivered ampoule into a 1.5 mL reaction 
vessel with screw cap, and the solvent was removed in a vacuum concentrator (30 °C, 30 
min). A solution of the precursor peptide [Lys4]hPP (7) (0.35 mg, 81 nmol in 0.1 M sodium 
borate buffer pH 9.5) (135 µL) was added, the vessel was vigorously shaken at rt for 2.5 h, 
and diluted by the addition of MeCN/0.05% aq TFA 30:70 (v/v) (215 μL). [3H]8 was purified 
using a HPLC system from Waters. A Synergi Hydro-RP C18, 4 μm, 250 × 4.6 mm 
(Phenomenex) served as stationary phase at a flow rate of 0.8 mL/min. Acetonitrile 
supplemented with 0.04% TFA (A) and 0.05% aq TFA (B) were used as mobile phase (linear 
gradient: 0–30 min: A/B 30:70–42:58, 30–31 min: 42:58–95:5, 31–40 min: 95:5). For the 
purification of the radiolabeled peptide five HPLC runs were performed. The radioligand was 
collected in 2-mL reaction vessels with screw caps, and the solvent of the combined eluates 
was removed in a vacuum concentrator. The product was dissolved in a mixture of 
EtOH/10 mM HCl 2:98 (v/v) (400 μL). To determine the radiochemical purity and to prove the 
identity of the radioligand, a solution of the radiolabeled peptide (0.07 µM), spiked with ‘cold’ 
8 (final concentration: 18 µM), was analyzed by HPLC with combined UV/radiochemical 
detection (linear gradient: 0–30 min: A/B 30:70–45:55, 30–31 min: 42:58–95:5, 31–40 min: 
95:5; injection volume: 100 µL). The radiochemical purity was 90%. For the quantification of 
the radioligand, an aliquot (2 μL) of the stock solution of [3H]8 in EtOH/10 mM HCl 2:98 was 
added to 118 μL of MeCN/0.05% aq TFA 30:70 (v/v), and 110 μL of this solution were 
injected (performed in duplicate). By four-point calibration with 8 (0.2, 0.5, 1.0, 3.0 µM; 
injection volume: 110 μL, UV-detection: 220 nm) a concentration of the radioligand of 
24.5 µM was determined. The activity of [3H]8 was determined as follows: two samples were 
prepared by diluting 1 μL of stock solution by adding 199 μL of acetonitrile/water 30:70. From 
each sample, 50 μL were counted in 3 mL of scintillator (Rotiszint eco plus) with a Beckman 
LS 6500 liquid scintillation counter in triplicate. Calculated specific activity: 34.91 Ci/mmol 
(1.291 TBq/mmol). Chemical yield: penta(hydrotrifluoroacetate) of [³H]8: 41.5 μg, 9.80 nmol, 
46.2%. Radiochemical yield: 0.342 mCi (12.65 MBq), 20.1% in 400 µL. The stock solution of 
[³H]8 (c = 24.5 μM) was stored at 4 °C. 
HPLC analyses (radiodetection) performed after storage for two week revealed slight 
decomposition of [³H]8. Therefore, ascorbic acid (final concentration: 0.24 mM) was added. 
However, after storage at 4 °C for 2 years analysis of the radioligand (radiolabeled peptide 
(0.44 µM), spiked with ‘cold’ 8 (final concentration: 18 µM); linear gradient: 0–30 min: A/B 
30:70–42:58, 30–31 min: 42:58–95:5, 31–40 min: 95:5; injection volume: 100 µL) repeated 
revealed a decomposition of the radioligand by 95%. 
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5.5.2 Synthesis of [Lys4,Nle17,30]hPP (11) 
SPPS was performed automatically on a Syro-I peptide synthesizer (Biotage, Uppsala, 
Sweden) by using the Fmoc/tBu strategy. The peptide-chain assembly was performed on a 
0.018 mmol scale on the Fmoc-Rink amide MBHA resin. The amino-acid (AA) double 
couplings (2 x 40 min) were carried out by using Fmoc-AA-OH/HOBt (5 eq. each), HBTU 
(4.9 eq.), and DIPEA (10 eq.) in DMF/NMP (7:3 v/v). Fmoc cleavage was carried out with a 
3 min treatment with 30% piperidine in DMF, followed by a 14 min treatment with 15% 
piperidine in DMF. After the peptide-chain assembly was completed, the resin was washed 
with DMF, DCM and Et2O (three times each) and vacuum dried overnight. The fully 
deprotected peptide was cleaved from the resin by using TFA/H2O/TIA/TIS/EDT (90:3:2:2:3 
v/v). After 3 h, the peptide was precipitated with cold Et2O and isolated by centrifugation at 8 
°C for 5 min. The crude peptide was further washed three times with cold Et2O to remove the 
residual scavengers and, finally, vacuum dried overnight. The product was purified by 
preparative HPLC (220 nm; column: YMC-Actus-Triart C8 250 x 20 mm ID, S 5 µm,12 nm; 
gradient: MeCN/0.1% aq TFA: 0–30 min: 10:90 – 50:50, 31–36 min: 90:10; flow rate: 20 
mL/min; tR = 24.8 min). HRMS (m/z): [M+6H]6+ calcd. for C188H296N54O52, 691.3769; found, 
691.3795. C188H296N54O52 · C12H6F18O12 (4144.69 + 684.12). 
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5.5.3 Purity, identity and long-term stability of [³H]8 determined by HPLC 
 
 
Figure S1. HPLC analysis for purity and 
identity control of the radiolabeled 
peptide [3H]propionyl-[Lys4]hPP ([³H]8) 
(0.17 µM) (red), spiked with ‘cold’ 8 
(18 µM). tR = 16.2 min; injection volume: 
100 µL. 
Radiochemical purity: 90 %. The minor 
differences in tR result from serial 
detection of the UV and radiometric 
signals. 
 
 
Figure S2. HPLC analysis of [³H]8 
(0.44 µM) (red), spiked with ‘cold’ 8 
(18 µM), analyzed after 2 years of storage 
at 4 °C in EtOH/10 mM HCl 2/98 (v/v), 
supplemented with ascorbic acid 
(0.24 mM). tR = 18.4 min; injection 
volume: 100 µL. A different gradient was 
applied compared to HPLC analysis in 
Figure S1.  
Radiochemical purity after 2 years: 5 %. 
The minor differences in tR result from 
serial detection of the UV and radiometric 
signals.  
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5.5.4 Chemical stability of the peptides hPP and 7-11 
 
 
Figure S3. Reversed-phase HPLC analysis of hPP after incubation in phosphate buffered saline 
(PBS, pH 7.4) at 21 °C for 48 h (detection at 220 nm). The peptide was stable under these conditions. 
 
Figure S4. Reversed-phase HPLC analysis of 7 after incubation in PBS (pH 7.4) at 21 °C for 48 h 
(detection at 220 nm). The peptide was stable under these conditions. 
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Figure S5. Reversed-phase HPLC analysis of 8 after incubation in PBS (pH 7.4) at 21 °C for 48 h 
(detection at 220 nm). The peptide was stable under these conditions. 
 
 
Figure S6. Reversed-phase HPLC analysis of 9 after incubation in PBS (pH 7.4) at 21 °C for 48 h 
(detection at 220 nm). The peptide was stable under these conditions.  
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Figure S7. Reversed-phase HPLC analysis of 10 after incubation in PBS (pH 7.4) at 21 °C for 48 h 
(detection at 220 nm). The peptide was stable under these conditions.  
  
Figure S8. Reversed-phase HPLC analysis of 11 after incubation in PBS (pH 7.4) at 21 °C for 48 h 
(detection at 220 nm). The peptide was stable under these conditions. 
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5.5.5 Fluorescence spectra and quantum yields of peptide 13 
 
Figure S9. Excitation and corrected emission spectrum of 13 in PBS pH 7.4 supplemented with 1% 
BSA (c = 3.2 μM). Spectrum was recorded with a Cary Eclipse spectrofluorimeter at 22 °C with the slit 
adjustments (ex./em. slit) 5/10 nm for excitation and 10/5 nm for emission. 
 
Table S1. Excitation and emission maxima and fluorescence quantum yields Φ (22 °C, cresyl 
violet perchlorate as reference), of the cyanine labeled peptide 13, determined in PBS and 
PBS supplemented with 1% BSA. 
 
PBS, pH 7.4  PBS, pH 7.4 containing 1% BSA 
λex/λem Φ (%)  λex/λem Φ (%) 
646/664 21  655/667 56 
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5.5.6 Osmolality of the buffers used in NPY receptor binding studies  
 
Table S2. Osmolality values determined for different buffers using a semi-micro osmometer 
(K-7400, Knauer, Berlin, Germany). 
 
Buffer buffer I buffer II buffer I buffer I  buffer I buffer I  
Containing no sodium NaCl  
150 mM 
NaCl  
50 mM 
NaCl 50 mM 
glycine 0.19 M 
NaCl  
100 mM 
glycine 
0.3 M 
mosmol/kg 51 353 142 360 283 370 
 
 
 
5.5.7 Saturation binding with [³H]8 at the hY4R 
 
 
Figure S10. Representative Y4R saturation 
binding of the radioligand [³H]8 determined 
at CHO-hY4-Gqi5-mtAEQ cells at 22 °C in 
buffer II. Nonspecific binding was 
determined in the presence of a 200-fold 
excess of 7. Three independent experiments 
were performed in triplicate;   Kd = 6.0 ± 
1.3 nM. 
 
5.5.8 Kinetic experiments with [³H]8 at the hY4R 
 
Figure S11. Kinetic experiments of the radioligand [³H]8 determined at CHO-hY4-Gqi5-mtAEQ cells at 
22 °C in buffer II. (A) Representative Y4R association kinetics of [³H]8; (c = 10 nM). Inset: Linearization 
ln[Beq/(Beq-Bt)] versus time. (B) Representative Y4R dissociation kinetics of [³H]8 (c = 10 nM, pre-
incubation time: 90 min) determined in the presence of a 100-fold excess of 7. Fitting of the data 
according to a monophasic exponential decay. Inset: Linearization ln[B/B0] versus time. Two 
independent experiments were performed in triplicate.  
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5.5.9 Saturation binding with [³H]12 at the hY4R 
 
Figure S12. (A) Representative saturation binding experiment with [3H]12 at CHO-hY4R-Gqi5-mtAEQ 
cells in buffer I supplemented with NaCl (final concentration 50 mM) ([3H]12: Kd = 7.2 ± 0.5 nM). (B) 
Representative saturation binding experiment with [3H]12 at CHO-hY4R-Gqi5-mtAEQ cells in buffer I 
supplemented with NaCl (final concentration 50 mM) adjusted to isotonic conditions with glycine (final 
concentration 0.19 M) ([3H]12: Kd  = 8.4 ± 0.9 nM). (C) Representative saturation binding experiment 
with [3H]12 at CHO-hY4R-Gqi5-mtAEQ cells in buffer I supplemented with NaCl (final concentration 
100 mM) ([3H]12: Kd= 18.0 ± 0.5 nM). Nonspecific binding was determined in the presence of a 100-
fold excess of 11. At least two independent experiments were performed in triplicate.  
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5.5.10 Binding characteristics of the fluorescent ligand 13 in buffer I containing 
glycine at the hY4R 
 
Figure S13. Y4R binding characteristics of the fluorescent ligand 13 determined by flow cytometry at 
CHO-hY4-Gqi5-mtAEQ cells in buffer I supplemented with glycine (final concentration 0.3 M). 
(A) Representative saturation binding experiments with 13. Nonspecific binding was determined in the 
presence of a 100-fold excess of hPP. (B) Representative Y4R dissociation kinetics of 13 (c = 10 nM; 
pre-incubation time: 60 min) determined in the presence of a 80-fold excess of [Lys
4
]hPP (7). 
Nonspecific binding was determined in the presence of a 100-fold excess of 7. Dissociation of 13 was 
not observed. Two independent experiments were performed in duplicate. 
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5.5.11 Morphology and volumes of CHO-hY4R cells under hypotonic and 
isotonic conditions 
 
 
Figure S14. Morphology of CHO-hY4-Gqi5-mtAEQ cells in isotonic buffer II (A), buffer I containing 
glycine (0.3 M) to obtain isotonicity (B), and hypotonic buffer I (C). (D) Comparison of the cell volumes 
in different buffers, calculated for spheres (n = 25; mean values  SEM).  
CHO-hY4-Gqi5-mtAEQ cells from a 75-cm2 culture flask were treated with 3 mL trypsin/EDTA. Aliquots 
of 1 mL were added to 9 mL of the respective buffer (buffer I, buffer I containing 0.3 M glycine and 
buffer II) before centrifugation (400 g, 5 min). Afterwards, the supernatants were discarded, and the 
cells were resuspended in the respective buffer (200 µL). Cells were examined in a hemocytometer 
(Neubauer improved, BLAUBRAND, Brand, Wertheim, Germany) using a Leitz DMRB microscope 
(Leica Microsystems, Wetzlar, Germany) with a PL Fluorstar objective (morphology: 10x/0.30; 
diameter: 40x/0.7, pH2) with a DCM-510 ocular microscope camera (OCS.tec, Erding, Germany). 
Diameters of 25 cells were measured in each buffer by using the ScopePhoto V3.0.12.498 software 
(Hangzhou Scopetek Opto-electric, Hangzhou, China). The volumes of the cells were calculated 
assuming spheres (4/3×π×r3). Images of the cells were taken in the respective buffer (10x objective).  
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5.5.12 Scattergrams of CHO-hY4R cells in the presence of 13 in different 
buffers 
 
Figure S15. Scattergrams of CHO-hY4RGqi5-mtAEQ cells in the presence of the labeled peptide 13 
(140 nM) in hypotonic buffer I (A), isotonic buffer II (B) and isotonic buffer I containing 0.3 M glycine 
(C). The subpopulation framed in black was chosen for binding studies. 
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5.5.13 Competition binding with [³H]8 at the hY4R 
 
 
Figure S16. Displacement curves from 
competition binding experiments performed 
with [³H]propionyl-[Lys4]hPP (Kd = 6.0 nM, 
c = 5 nM) using CHO-hY4RGqi5-mtAEQ cells in 
buffer II. Data represent mean values ± SEM 
from at least two independent experiments 
performed in triplicate. 
 
  
5.5.14 Saturation binding with [³H]propionyl-pNPY at the hY1R, hY2R, and 
hY5R 
 
Figure S17. (A) Representative saturation binding experiment with [3H]propionyl-pNPY at MCF-7-hY1 
cells in buffer I containing 0.3 M glycine (Kd = 5.1 ± 1.9 nM). (B) Representative saturation binding 
experiment with [3H]propionyl-pNPY at MCF-7-hY1 cells in buffer II (Kd = 6.6 ± 0.3 nM). At least two 
independent experiments were performed in triplicate. 
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Figure S18. (A) Representative saturation binding experiment with [3H]propionyl-pNPY at CHO-hY2R-
Gqi5-mtAEQ cells in buffer I (Kd= 1.4 ± 0.1 nM) (n=4). (B) Representative binding experiment with 
[3H]propionyl-pNPY at CHO-hY2R-Gqi5-mtAEQ cells in buffer I containing 0.3 M glycine (n=2). 
(C) Representative binding experiment with [3H]propionyl-pNPY at CHO-hY2R-Gqi5-mtAEQ cells in 
buffer I containing 0.3 M sucrose (n=2). (D) Representative binding experiment with [3H]propionyl-
pNPY at CHO-hY2R-Gqi5-mtAEQ cells in buffer II (n=3). Experiments were performed in triplicate. 
 
 
Figure S19. (A) Representative saturation binding experiment with [3H]propionyl-pNPY at HEC-1B-hY5 
cells in buffer I supplemented with glycine (final concentration 0.3 M) (Kd = 24.5 ± 4.9 nM). 
(B) Representative saturation binding experiment with [3H]propionyl-pNPY at HEC-1B-hY5 cells in 
buffer II (Kd = 11.0 ± 2.1 nM). Nonspecific binding was determined in the presence of a 100-fold excess 
of pNPY. At least two independent experiments were performed in triplicate. 
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5.5.15 Saturation binding with [³H]8 at the hY5R 
 
 
Figure S20. Representative saturation binding 
experiment of the radioligand [³H]8 determined 
at HEC-1B-hY5R cells at 22 °C in buffer II. 
Nonspecific binding was determined in the 
presence of a 200-fold excess of CGP 71683A. 
Three independent experiments were performed 
in triplicate; Kd = 6.9 ± 0.9 nM. 
 
5.5.16 Saturation binding with [³H]12 at the hY5R 
 
Figure S21. (A) Representative saturation binding experiment with [3H]12 at HEC-1B-hY5 cells in 
buffer I supplemented with glycine (final concentration 0.3 M) (Kd = 16.4 ± 2.3 nM). (B) Representative 
saturation binding experiment with [3H]12 at HEC-1B-hY5 cells in buffer II (Kd = 11.4 ± 0.2 nM). Three 
independent experiments were performed in triplicate. 
 
5.5.17 Saturation binding with 13 at the hY5R 
 
 
Figure S22. Representative saturation binding 
experiment of 13 on HEC-1B-hY5R cells in 
buffer II. Kd = 26.5 ± 4.8 nM; nonspecific binding 
was determined in the presence of an 80-fold 
excess of CGP 71683A; three independent 
experiments were performed in duplicate; assay 
was performed as previously described for 
saturation binding experiments with 13 on CHO 
hY4R cells. 
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104 Summary 
The neuropeptide Y (NPY) family comprises the 36-amino acid peptides neuropeptide Y 
(NPY), peptide YY (PYY), and pancreatic polypeptide (PP). In humans, the biological effects 
of these peptides are mediated by four functionally expressed receptor subtypes, designated 
Y1, Y2, Y4 and Y5 receptors (Y1R, Y2R, Y4R, Y5R). Among the NPY receptors the Y4R is 
unique, as it prefers PP over NPY and PYY as the endogenous ligand. PP is predominantly 
expressed in an endocrine cell type (PP cells) of the pancreas, and is, for example, 
considered to be involved in satiety signaling, the regulation of food intake and energy 
metabolism. With this in view, Y4R agonists are discussed as potential anti-obesity drugs. For 
the characterization of Y2 and Y4R ligands, pharmacological tools are indispensable. 
Therefore, the first part of this work was aiming at establishing a [35S]GTPγS binding assay 
and a luciferase gene reporter assay for the hY2R and hY4R, since these assays complement 
each other by providing different readouts. The second part of this thesis aimed at the 
development of full length radio- and fluorescence-labeled hPP analogs, which are more 
stable compared to the endogenous ligand and [Lys4]hPP. 
In the [35S]GTPγS binding assay at the hY2R, pharmacological data of selected agonists and 
antagonists were in good agreement with functional studies in the steady-state GTPase 
assay and the calcium mobilization assay at the hY2R. Most strikingly, the [35S]GTPγS assay 
at the hY4R revealed potencies of hPP and GW1229, which were lower by a factor 19 and 
180, respectively, compared to reported data for the steady-state GTPase assay. Further 
investigations at the Y4R revealed that the signal-to-noise ratio was not improved by the 
variation of the Mg2+ ion concentration. Increasing Na+ concentrations led to minor changes 
of the potency of hPP, whereas [Lys4]hPP and GW1229 were markedly less potent in the 
presence of sodium. This is in agreement with the data from radioligand binding assays at 
the hY4R. Nevertheless, the [35S]GTPγS assay is compromised by a low signal-to-noise ratio 
impairing the robustness of the data.  
By using a CRE-controlled luciferase reporter gene assay, agonistic and antagonistic 
activities of several ligands could be determined in HEK293T cells, stably expressing the 
human Y2 and Y4 receptor, respectively. The conditions were optimized regarding 
concentration of the vehicle (DMSO or DMF), the forskolin concentration, the period of 
incubation and the addition of bacitracin as a protease inhibitor. Although a tremendous 
reduction of the bioluminescene signal by DMSO and DMF became obvious, at 
concentrations <0.2%, required to keep forskolin (2 µM) and test compounds in solution 
(over 4.5 h), the effect of the solvent was negligible. Under optimized conditions the 
determined potencies of selected ligands at the respective receptor were generally higher 
compared to reported results from other functional assays.  
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For the development of radio- and fluorescence-labeled hPP analogs, we selected 
[Lys4,Nle17,30]hPP as a template, as the methionine residues in position 17 and 30 in 
[Lys4]hPP are prone to oxidation. [³H]propionyl-[Lys4,Nle17,30]hPP and the cyanine-labeled 
fluorescent peptide S0223[Lys4,Nle17,30]hPP were synthesized and characterized in 
saturation and kinetic Y4R binding experiments, in functional studies and with respect to NPY 
receptor subtype selectivity. Interestingly, radioligand affinity (Kd in Na+-free buffer: 1.1 nM) 
clearly decreased with increasing sodium ion concentration, whereas dissociation and Y4R-
mediated internalization of the fluorescent ligand (Kd in Na+-free buffer: 10.8 nM) were 
strongly effected by the osmolarity of the buffer as demonstrated by confocal microscopy. 
The labeled compounds were also used to determine the affinities of unlabeled compounds 
in competition binding assays. Displacement of the labeled ligands revealed a tendency to 
higher apparent affinities for a set of reference peptides in hypotonic (Na+-free) compared to 
isotonic buffers. The differences were negligible in case of hPP but up to 270-fold in case of 
GW1229 (GR231118). However, it could be demonstrated that, despite an identical peptide 
scaffold, fundamental differences between both types of probes might exist and should be 
carefully taken into account in the interpretation of experimental results. 
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Figure 7.1. Representative saturation binding experiment of [3H]propionyl-pNPY on SK-N-MC cells 
expressing the Y1R. Kd = 1.9 ± 0.3 nM (Keller et al., 2015); nonspecific binding was determined in the 
presence of BIBP3226; two independent experiments were performed in triplicate in 48-well format. 
 
    
Figure 7.2. Binding experiments with [3H]propionyl-pNPY (5 nM) at CHO cells expressing the Y2R in 
different buffer systems. Differences in total (transparent columns) and specific binding (red columns) 
of the radioligand could be observed at the Y2R dependent on the used buffer. Total binding in buffer I 
was set to 100%. Nonspecific binding was determined in the presence of 1 µM pNPY. Composition of 
buffer I and buffer II see section 5.2.6; D-PBS (1.8 mM CaCl2, 2.68 mM KCl, 1.47 mM KH2PO4, 
3.98 mM MgSO4 · 7H2O, 136.9 mM NaCl, 8.06 mM Na2HPO4 · 7H2O), Gibco Leibovitz's L-15 medium 
(containing 140 mM NaCl, 1.3 mM CaCl2, 1 mM MgCl2, amino acids, vitamins, pH 7.4). Experiment 
was performed in triplicate in Primaria 24-well plates; plates were processed as previously described 
for [³H]propionyl-[Lys4]hPP (see section 5.2.7). 
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Table 7.1. Determination of Ki values on NPY receptor subtypes.  
 Ki [nM] 
Compound Y1Ra Y2Rb Y4Rc Y5Rd 
BIBP3226   4.8 ± 0.2 n.d. n.d. n.d. 
BIBO3304   1.1 ± 0.1 n.d. n.d. n.d. 
pNPY   4.4 ± 1.3 1.7 ± 0.13 n.d.   6.7 ± 1.1 
propionyl-pNPY 11.7 ± 0.9 2.1 ± 0.2 26.5 ± 4.1 10.3 ± 0.5 
pNPY 2-36    n.d. 5.8 ± 1.1 n.d. n.d. 
[a] Radioligand competition binding assay with [3H]propionyl-pNPY (Kd = 7 nM, c = 5 nM) using MCF-
7-hY1 cells (Keller et al., 2011) in buffer II. [b] Radioligand competition binding assay with 
[3H]propionyl-pNPY (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-mtAEQ cells (Ziemek et al., 2006) in 
buffer I. [c] Radioligand competition binding assay with [³H]propionyl-[Lys4,Nle17,30]hPP (Kd = 1.1 nM, 
c = 1 nM) using CHO-hY4RGqi5-mtAEQ cells (Ziemek et al., 2007) in buffer I. [d] Radioligand 
competition binding assay with [3H]propionyl-pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1B-hY5R cells 
in buffer II (Moser, 2000). Data represent mean values ± SEM from at least two independent 
experiments performed in triplicate. 
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